Pharmacokinetic	O
differences	O
between	O
a	O
T	O
cell-tolerizing	O
and	O
a	O
T	O
cell-activating	O
peptide	O
.	O

Vaccination	O
with	O
a	O
peptide	O
representing	O
a	O
CTL	O
epitope	O
from	O
the	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
16	O
E7	B-protein
protein	I-protein
induces	O
a	O
specific	O
CTL	O
response	O
that	O
prevents	O
the	O
outgrowth	O
of	O
HPV16	O
E7-expressing	O
tumors	O
.	O

In	O
contrast	O
,	O
vaccination	O
with	O
a	O
peptide	O
encoding	O
an	O
adenovirus	O
type	O
5	O
(	O
Ad5	O
)	O
E1A	O
CTL	O
epitope	O
results	O
in	O
CTL	O
tolerance	O
and	O
enhanced	O
growth	O
of	O
an	O
Ad5	O
E1A-expressing	O
tumor	O
.	O

It	O
is	O
unclear	O
why	O
these	O
peptides	O
induce	O
such	O
opposite	O
effects	O
.	O

To	O
determine	O
whether	O
a	O
difference	O
in	O
pharmacokinetics	O
can	O
explain	O
the	O
functional	O
contrasts	O
,	O
tritiated	O
Ad5	O
E1A	O
and	O
HPV16	O
E7	O
peptides	O
were	O
injected	O
into	O
mice	O
.	O

Results	O
show	O
that	O
the	O
tolerizing	O
peptide	O
spread	O
through	O
the	O
body	O
16	O
times	O
faster	O
than	O
the	O
activating	O
peptide	O
and	O
was	O
cleared	O
at	O
least	O
2	O
times	O
faster	O
.	O

The	O
HPV16	O
E7	O
peptide	O
kinetics	O
correlated	O
with	O
the	O
kinetics	O
of	O
HPV16	B-protein
E7	I-protein
-specific	O
CTL	O
induction	O
.	O

In	O
contrast	O
,	O
Ad5	O
E1A	O
peptide	O
injection	O
resulted	O
in	O
physical	O
deletion	O
of	O
preexisting	O
Ad5	B-protein
E1A	I-protein
-specific	O
CTLs	B-protein
within	O
24	O
h	O
after	O
injection	O
.	O

This	O
tolerization	O
occurred	O
at	O
the	O
time	O
when	O
the	O
peptide	O
reached	O
its	O
maximum	O
peptide	O
concentration	O
in	O
the	O
organs	O
.	O

These	O
data	O
suggest	O
that	O
ubiquitous	O
expression	O
of	O
the	O
tolerizing	O
Ad5	O
E1A	O
peptide	O
within	O
a	O
short	O
period	O
of	O
time	O
causes	O
activation-induced	O
cell	O
death	O
of	O
Ad5	B-protein
E1A	I-protein
-specific	O
CTLs	B-protein
.	O

Therefore	O
,	O
information	O
on	O
the	O
pharmacokinetics	O
of	O
peptides	O
is	O
vital	O
for	O
the	O
safety	O
and	O
efficacy	O
of	O
peptide-based	O
vaccines	O
.	O

BULK	NULL
ANTIBODIES	NULL
~	NULL
.	NULL

m	NULL
(	NULL
a-4-16	NULL
.	NULL

H	NULL
``	NULL
Th	NULL
VIVO	NULL
v	NULL
RE	NULL
SEAR	NULL
GCH	NULL
£	NULL
{	NULL
Discover	NULL
More	NULL
Me	NULL
Le	NULL
m	NULL
Journal	NULL
o	NULL
Pharmacokinetic	NULL
Differences	NULL
Between	NULL
a	NULL
T	NULL
A8	NULL
immunolo	NULL
gy	NULL
_	NULL
Cell-Tolerizing	NULL
and	NULL
a	NULL
T	NULL
Cell-Activating	NULL
Peptide	NULL
This	NULL
inf	NULL
tion	NULL
i	NULL
t	NULL
Sanne	NULL
Weijzen	NULL
,	NULL
Stephen	NULL
C.	NULL
Meredith	NULL
,	NULL
Markwin	NULL
P.	NULL
Velders	NULL
,	NULL
of	NULL
£1	NULL
:	NULL
le	NULL
(	NULL
Tani	NULL
;	NULL
i	NULL
)	NULL
;	NULL
Is	NULL
current	NULL
as	NULL
Amira	NULL
G.	NULL
Elmishad	NULL
,	NULL
Hans	NULL
Schreiber	NULL
and	NULL
W.	NULL
Martin	NULL
Kast	NULL
J	NULL
Immunol	NULL
2001	NULL
;	NULL
166:7151-7157	NULL
;	NULL
;	NULL
doi	NULL
:	NULL
10.4049/jimmunol.166.12.7151	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/166/12/7151	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
28	NULL
articles	NULL
,	NULL
13	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/166/12/7151	NULL
.	NULL

full	NULL
#	NULL
ref-list-	NULL
1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_-	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
2001	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
Pharmacokinetic	NULL
Differences	NULL
Between	NULL
a	NULL
T	NULL
Cell-Tolerizing	NULL
and	NULL
a	NULL
T	NULL
Cell-Activating	NULL
Peptide	NULL
'	NULL
Sanne	NULL
Weijzen	NULL
,	NULL
*	NULL
Stephen	NULL
C.	NULL
Meredith	NULL
,	NULL
``	NULL
Markwin	NULL
P.	NULL
Velders	NULL
,	NULL
*	NULL
Amira	NULL
G.	NULL
Elmishad	NULL
,	NULL
*	NULL
Hans	NULL
Schreiber	NULL
,	NULL
``	NULL
and	NULL
W.	NULL
Martin	NULL
Kast	NULL
``	NULL
*	NULL
Vaccination	NULL
with	NULL
a	NULL
peptide	NULL
representing	NULL
a	NULL
CTL	NULL
epitope	NULL
from	NULL
the	NULL
human	NULL
papillomavirus	NULL
(	NULL
HPV	NULL
)	NULL
16	NULL
E7	NULL
protein	NULL
induces	NULL
a	NULL
specific	NULL
CTL	NULL
response	NULL
that	NULL
prevents	NULL
the	NULL
outgrowth	NULL
of	NULL
HPV16	NULL
E7-expressing	NULL
tumors	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
vaccination	NULL
with	NULL
a	NULL
peptide	NULL
encoding	NULL
an	NULL
adenovirus	NULL
type	NULL
5	NULL
(	NULL
Ad5	NULL
)	NULL
E1A	NULL
CTL	NULL
epitope	NULL
results	NULL
in	NULL
CTL	NULL
tolerance	NULL
and	NULL
enhanced	NULL
growth	NULL
of	NULL
an	NULL
Ad5	NULL
E1A-expressing	NULL
tumor	NULL
.	NULL

It	NULL
is	NULL
unclear	NULL
why	NULL
these	NULL
peptides	NULL
induce	NULL
such	NULL
opposite	NULL
effects	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
a	NULL
difference	NULL
in	NULL
pharmacokinetics	NULL
can	NULL
explain	NULL
the	NULL
functional	NULL
contrasts	NULL
,	NULL
tritiated	NULL
Ad5	NULL
E1A	NULL
and	NULL
HPV16	NULL
E7	NULL
peptides	NULL
were	NULL
injected	NULL
into	NULL
mice	NULL
.	NULL

Results	NULL
show	NULL
that	NULL
the	NULL
tolerizing	NULL
peptide	NULL
spread	NULL
through	NULL
the	NULL
body	NULL
16	NULL
times	NULL
faster	NULL
than	NULL
the	NULL
activating	NULL
peptide	NULL
and	NULL
was	NULL
cleared	NULL
at	NULL
least	NULL
2	NULL
times	NULL
faster	NULL
.	NULL

The	NULL
HPV16	NULL
E7	NULL
peptide	NULL
kinetics	NULL
correlated	NULL
with	NULL
the	NULL
kinetics	NULL
of	NULL
HPV16	NULL
E7-specific	NULL
CTL	NULL
induction	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
injection	NULL
resulted	NULL
in	NULL
physical	NULL
deletion	NULL
of	NULL
preexisting	NULL
Ad5	NULL
E1A-specific	NULL
CTLs	NULL
within	NULL
24	NULL
h	NULL
after	NULL
injection	NULL
.	NULL

This	NULL
tolerization	NULL
occurred	NULL
at	NULL
the	NULL
time	NULL
when	NULL
the	NULL
peptide	NULL
reached	NULL
its	NULL
maximum	NULL
peptide	NULL
concentration	NULL
in	NULL
the	NULL
organs	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
ubiquitous	NULL
expression	NULL
of	NULL
the	NULL
tolerizing	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
within	NULL
a	NULL
short	NULL
period	NULL
of	NULL
time	NULL
causes	NULL
activation-induced	NULL
cell	NULL
death	NULL
of	NULL
AdS	NULL
E1A-specific	NULL
CTLs	NULL
.	NULL

Therefore	NULL
,	NULL
information	NULL
on	NULL
the	NULL
pharmacokinetics	NULL
of	NULL
peptides	NULL
is	NULL
vital	NULL
for	NULL
the	NULL
safety	NULL
and	NULL
efficacy	NULL
of	NULL
peptide-based	NULL
vaccines	NULL
.	NULL

The	NULL
Journal	NULL
of	NULL
Immunology	NULL
,	NULL
2001	NULL
,	NULL
166	NULL
:	NULL
7151-7157.	NULL
protective	NULL
immunity	NULL
against	NULL
a	NULL
variety	NULL
of	NULL
infections	NULL
and	NULL
tumor	NULL
challenges	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

For	NULL
example	NULL
,	NULL
vaccination	NULL
with	NULL
a	NULL
CTL	NULL
epitope	NULL
from	NULL
the	NULL
human	NULL
papillomavirus	NULL
(	NULL
HPV	NULL
)	NULL
type	NULL
16	NULL
E7	NULL
protein	NULL
protected	NULL
mice	NULL
against	NULL
the	NULL
outgrowth	NULL
of	NULL
tumor	NULL
cells	NULL
expressing	NULL
the	NULL
HPV16	NULL
genome	NULL
(	NULL
3	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
some	NULL
tumor	NULL
models	NULL
,	NULL
peptide-based	NULL
vaccines	NULL
promote	NULL
tumor	NULL
growth	NULL
.	NULL

Examples	NULL
of	NULL
such	NULL
peptides	NULL
are	NULL
CTL	NULL
epitopes	NULL
derived	NULL
from	NULL
adenovirus	NULL
type	NULL
5	NULL
(	NULL
Ad5	NULL
)	NULL
E1A	NULL
(	NULL
4	NULL
)	NULL
and	NULL
E1B	NULL
(	NULL
5	NULL
)	NULL
and	NULL
the	NULL
CTL	NULL
epitope	NULL
derived	NULL
from	NULL
the	NULL
P815	NULL
mastocytoma	NULL
tumor	NULL
Ag	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Mice	NULL
that	NULL
were	NULL
immunized	NULL
s.c.	NULL
with	NULL
these	NULL
peptides	NULL
in	NULL
IFA	NULL
and	NULL
then	NULL
challenged	NULL
with	NULL
tumor	NULL
cells	NULL
expressing	NULL
the	NULL
Ags	NULL
developed	NULL
tumors	NULL
more	NULL
rapidly	NULL
than	NULL
nonimmu-nized	NULL
mice	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
functional	NULL
activity	NULL
of	NULL
Ad5	NULL
E1A-specific	NULL
CTLs	NULL
that	NULL
were	NULL
adoptively	NULL
transferred	NULL
into	NULL
nude	NULL
mice	NULL
was	NULL
no	NULL
longer	NULL
detectable	NULL
after	NULL
the	NULL
mice	NULL
were	NULL
immunized	NULL
with	NULL
the	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
when	NULL
mice	NULL
received	NULL
Ad5	NULL
E1A-specific	NULL
CTLs	NULL
i.v	NULL
.	NULL

and	NULL
the	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
s.c.	NULL
simultaneously	NULL
,	NULL
they	NULL
died	NULL
of	NULL
extensive	NULL
lung	NULL
destruction	NULL
within	NULL
16	NULL
h	NULL
after	NULL
injection	NULL
(	NULL
4	NULL
)	NULL
.	NULL

However	NULL
,	NULL
when	NULL
HPV16	NULL
E7-specific	NULL
CTLs	NULL
and	NULL
HPV16	NULL
E7	NULL
peptide	NULL
P	NULL
eptide-based	NULL
vaccines	NULL
have	NULL
been	NULL
successful	NULL
in	NULL
inducing	NULL
*Cardinal	NULL
Bernardin	NULL
Cancer	NULL
Center	NULL
,	NULL
Loyola	NULL
University	NULL
Chicago	NULL
,	NULL
Maywood	NULL
,	NULL
IL	NULL
60153	NULL
;	NULL
and	NULL
*University	NULL
of	NULL
Chicago	NULL
,	NULL
Chicago	NULL
IL	NULL
60637	NULL
Received	NULL
for	NULL
publication	NULL
February	NULL
5	NULL
,	NULL
2001	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
April	NULL
5	NULL
,	NULL
2001	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
adverfisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
'	NULL

This	NULL
project	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grants	NULL
PO1	NULL
CA	NULL
74182	NULL
(	NULL
to	NULL
W.M.K	NULL
.	NULL

,	NULL
H.S	NULL
.	NULL

,	NULL
and	NULL
S.C.M	NULL
.	NULL
)	NULL

and	NULL
RO1	NULL
CA/AI	NULL
78399	NULL
(	NULL
to	NULL
W.M.K	NULL
.	NULL
)	NULL

.	NULL

M.P.V	NULL
.	NULL

is	NULL
a	NULL
fellow	NULL
of	NULL
the	NULL
Cancer	NULL
Research	NULL
Institute	NULL
.	NULL

2	NULL
Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
W.	NULL
Martin	NULL
Kast	NULL
,	NULL
Cardinal	NULL
Bernardin	NULL
Cancer	NULL
Center	NULL
,	NULL
Loyola	NULL
University	NULL
Chicago	NULL
,	NULL
2160	NULL
South	NULL
First	NULL
Avenue	NULL
,	NULL
Maywood	NULL
,	NULL
IL	NULL
60153	NULL
.	NULL

E-mail	NULL
address	NULL
:	NULL
mkast	NULL
@	NULL
lumc.edu	NULL
°	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
HPV	NULL
,	NULL
human	NULL
papilloma	NULL
virus	NULL
;	NULL
Ad5	NULL
,	NULL
Adenovirus	NULL
type	NULL
5	NULL
;	NULL
TFA	NULL
,	NULL
trifluoroacetic	NULL
acid	NULL
;	NULL
ELISPOT	NULL
,	NULL
enzyme-linked	NULL
immunospot	NULL
;	NULL
AICD	NULL
,	NULL
activation-induced	NULL
cell	NULL
death	NULL
;	NULL
DC	NULL
,	NULL
dendritic	NULL
cell	NULL
.	NULL

Copyright	NULL
©	NULL
2001	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
were	NULL
injected	NULL
simultaneously	NULL
,	NULL
lung	NULL
destruction	NULL
did	NULL
not	NULL
occur	NULL
and	NULL
CTLs	NULL
remained	NULL
functionally	NULL
active	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
there	NULL
is	NULL
an	NULL
important	NULL
difference	NULL
between	NULL
the	NULL
HPV16	NULL
E7	NULL
and	NULL
Ad5	NULL
E1A	NULL
peptides	NULL
,	NULL
which	NULL
could	NULL
be	NULL
related	NULL
to	NULL
a	NULL
difference	NULL
in	NULL
diffusion	NULL
rates	NULL
throughout	NULL
the	NULL
body	NULL
.	NULL

In	NULL
the	NULL
human	NULL
setting	NULL
,	NULL
peptide-based	NULL
vaccines	NULL
have	NULL
also	NULL
induced	NULL
diverse	NULL
effects	NULL
.	NULL

Several	NULL
clinical	NULL
trials	NULL
applying	NULL
peptide-based	NULL
vaccines	NULL
in	NULL
cancer	NULL
patients	NULL
have	NULL
demonstrated	NULL
peptide-specific	NULL
immune	NULL
responses	NULL
in	NULL
the	NULL
majority	NULL
of	NULL
the	NULL
patients	NULL
(	NULL
7-10	NULL
)	NULL
.	NULL

However	NULL
,	NULL
many	NULL
of	NULL
the	NULL
clinical	NULL
trials	NULL
testing	NULL
peptide-based	NULL
vaccines	NULL
have	NULL
shown	NULL
limited	NULL
or	NULL
no	NULL
peptide-specific	NULL
immune	NULL
response	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
with	NULL
undetectable	NULL
clinical	NULL
effects	NULL
(	NULL
13-15	NULL
)	NULL
.	NULL

Although	NULL
many	NULL
explanations	NULL
for	NULL
the	NULL
absence	NULL
of	NULL
immune	NULL
induction	NULL
have	NULL
been	NULL
offered	NULL
,	NULL
the	NULL
deletion	NULL
of	NULL
specific	NULL
CTLs	NULL
after	NULL
peptide	NULL
vaccination	NULL
has	NULL
not	NULL
been	NULL
studied	NULL
.	NULL

Moreover	NULL
,	NULL
vaccination-induced	NULL
T	NULL
cell	NULL
tolerance	NULL
would	NULL
be	NULL
deleterious	NULL
to	NULL
the	NULL
desired	NULL
objective	NULL
of	NULL
establishing	NULL
immunity	NULL
and	NULL
to	NULL
the	NULL
immediate	NULL
health	NULL
of	NULL
the	NULL
patients	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
is	NULL
important	NULL
to	NULL
determine	NULL
why	NULL
peptide-based	NULL
vaccines	NULL
can	NULL
give	NULL
such	NULL
contrasting	NULL
results	NULL
.	NULL

To	NULL
our	NULL
knowledge	NULL
,	NULL
there	NULL
is	NULL
no	NULL
published	NULL
study	NULL
that	NULL
has	NULL
explored	NULL
a	NULL
possible	NULL
difference	NULL
in	NULL
pharmacokinetics	NULL
as	NULL
an	NULL
important	NULL
property	NULL
that	NULL
determines	NULL
immunogenicity	NULL
of	NULL
peptides	NULL
in	NULL
vivo	NULL
.	NULL

Information	NULL
on	NULL
peptide	NULL
pharmacokinetics	NULL
could	NULL
greatly	NULL
influence	NULL
the	NULL
design	NULL
of	NULL
peptide-based	NULL
vaccine	NULL
strategies	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
compared	NULL
the	NULL
pharmacokinetics	NULL
of	NULL
a	NULL
T	NULL
cell-activating	NULL
peptide	NULL
derived	NULL
from	NULL
the	NULL
HPV16	NULL
E7	NULL
protein	NULL
and	NULL
a	NULL
T	NULL
cell-tolerizing	NULL
peptide	NULL
of	NULL
the	NULL
Ad5	NULL
E1A	NULL
protein	NULL
.	NULL

The	NULL
results	NULL
show	NULL
that	NULL
the	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
egressed	NULL
from	NULL
the	NULL
vaccine	NULL
site	NULL
at	NULL
a	NULL
higher	NULL
rate	NULL
than	NULL
the	NULL
HPV16	NULL
E7	NULL
peptide	NULL
.	NULL

As	NULL
a	NULL
consequence	NULL
,	NULL
the	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
reached	NULL
its	NULL
maximum	NULL
concentration	NULL
in	NULL
all	NULL
organs	NULL
much	NULL
faster	NULL
than	NULL
the	NULL
HPV16	NULL
E7	NULL
peptide	NULL
;	NULL
maximum	NULL
concentrations	NULL
were	NULL
reached	NULL
at	NULL
~10	NULL
and	NULL
160	NULL
h	NULL
in	NULL
all	NULL
organs	NULL
for	NULL
the	NULL
Ad5	NULL
E1A	NULL
and	NULL
the	NULL
HPV16	NULL
E7	NULL
peptide	NULL
,	NULL
respectively	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
HPV16	NULL
E7	NULL
peptide	NULL
remained	NULL
in	NULL
all	NULL
organs	NULL
significantly	NULL
longer	NULL
than	NULL
the	NULL
Ad5	NULL
ElA	NULL
peptide	NULL
.	NULL

These	NULL
differences	NULL
in	NULL
pharmacokinetics	NULL
could	NULL
contribute	NULL
to	NULL
the	NULL
differential	NULL
effects	NULL
of	NULL
HPV16	NULL
E7	NULL
and	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
injection	NULL
on	NULL
peptide-specific	NULL
CTLs	NULL
in	NULL
vivo	NULL
.	NULL

0022-1767/01/	NULL
$	NULL
02.00	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
7152	NULL
IN	NULL
VIVO	NULL
KINETICS	NULL
OF	NULL
A	NULL
TOLERIZING	NULL
AND	NULL
AN	NULL
ACTIVATING	NULL
PEPTIDE	NULL
Materials	NULL
and	NULL
Methods	NULL
Mice	NULL
,	NULL
cell	NULL
lines	NULL
,	NULL
and	NULL
peptides	NULL
Six-week-old	NULL
female	NULL
C57BL/6	NULL
mice	NULL
were	NULL
purchased	NULL
from	NULL
Taconic	NULL
Farms	NULL
(	NULL
Germantown	NULL
,	NULL
NY	NULL
)	NULL
and	NULL
were	NULL
housed	NULL
in	NULL
a	NULL
specified	NULL
pathogen-free	NULL
environ-ment	NULL
.	NULL

RMA-S	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
IMDM	NULL
(	NULL
BioWhittaker	NULL
,	NULL
Walkersville	NULL
,	NULL
MD	NULL
)	NULL
supplemented	NULL
with	NULL
2	NULL
mM	NULL
L-glutamine	NULL
(	NULL
Mediatech	NULL
,	NULL
Herndon	NULL
,	NULL
VA	NULL
)	NULL
,	NULL
10	NULL
%	NULL
FCS	NULL
(	NULL
HyClone	NULL
Laboratories	NULL
,	NULL
Logan	NULL
,	NULL
UT	NULL
)	NULL
,	NULL
and	NULL
1	NULL
mg/ml	NULL
kanamycin	NULL
(	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

Peptides	NULL
were	NULL
dissolved	NULL
in	NULL
PBS	NULL
and	NULL
emulsified	NULL
in	NULL
IFA	NULL
(	NULL
Difco	NULL
,	NULL
Detroit	NULL
,	NULL
MI	NULL
)	NULL
at	NULL
a	NULL
ratio	NULL
of	NULL
1:1	NULL
using	NULL
the	NULL
Polytron	NULL
homogenizer	NULL
PT-3100	NULL
(	NULL
Brinkmann	NULL
Instruments	NULL
,	NULL
Westbury	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

This	NULL
method	NULL
of	NULL
emulsification	NULL
of	NULL
peptides	NULL
is	NULL
superior	NULL
to	NULL
the	NULL
classical	NULL
method	NULL
of	NULL
emulsification	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
vortexing	NULL
or	NULL
repeatedly	NULL
passing	NULL
through	NULL
a	NULL
syringe	NULL
)	NULL
.	NULL

This	NULL
method	NULL
guaranteed	NULL
that	NULL
both	NULL
peptides	NULL
were	NULL
equally	NULL
well	NULL
emulsified	NULL
.	NULL

A	NULL
total	NULL
of	NULL
300	NULL
ug	NULL
of	NULL
°H-labeled	NULL
peptide	NULL
,	NULL
equivalent	NULL
to	NULL
0.51	NULL
mCi	NULL
°H	NULL
,	NULL
was	NULL
injected	NULL
s.c.	NULL
in	NULL
a	NULL
volume	NULL
of	NULL
250	NULL
ul	NULL
on	NULL
the	NULL
right	NULL
flank	NULL
of	NULL
the	NULL
mouse	NULL
.	NULL

Peptide	NULL
synthesis	NULL
AdS	NULL
ElA	NULL
»	NULL
,	NULL
;	NULL
43	NULL
(	NULL
NH	NULL
,	NULL
-SGPSNTPPEI-COOH	NULL
)	NULL
(	NULL
16	NULL
)	NULL
and	NULL
HPV16	NULL
EZ	NULL
,	NULL
,	NULL
;	NULL
;	NULL
(	NULL
NH	NULL
,	NULL
-RAHYNIVTE-COOH	NULL
)	NULL
(	NULL
3	NULL
)	NULL
were	NULL
synthesized	NULL
and	NULL
purified	NULL
as	NULL
reported	NULL
previously	NULL
for	NULL
``	NULL
C-labeled	NULL
peptides	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
uniformly	NULL
labeled	NULL
°H-L-Ile	NULL
(	NULL
New	NULL
England	NULL
Nuclear	NULL
,	NULL
Billerica	NULL
,	NULL
MA	NULL
)	NULL
with	NULL
a	NULL
specific	NULL
radioactivity	NULL
of	NULL
108	NULL
Ci/mmol	NULL
were	NULL
protected	NULL
by	NULL
tBOC	NULL
or	NULL
F-moc	NULL
groups	NULL
as	NULL
described	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Peptides	NULL
were	NULL
dissolved	NULL
in	NULL
0.1	NULL
%	NULL
trifluoroacetic	NULL
acid	NULL
(	NULL
TFA	NULL
)	NULL
and	NULL
purified	NULL
by	NULL
preparative	NULL
reverse	NULL
phase	NULL
HPLC	NULL
using	NULL
a	NULL
Rainin	NULL
Dynamax	NULL
SD-200	NULL
HPLC	NULL
(	NULL
Rainin	NULL
Instruments	NULL
,	NULL
Emeryville	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
a	NULL
Zorbax	NULL
300-SB	NULL
C4	NULL
column	NULL
(	NULL
MAC-MOD	NULL
An-alytical	NULL
,	NULL
Chaddsford	NULL
,	NULL
PA	NULL
)	NULL
.	NULL

Purity	NULL
was	NULL
assessed	NULL
by	NULL
analytical	NULL
HPLC	NULL
using	NULL
a	NULL
Rainin	NULL
25	NULL
X	NULL
0.5	NULL
cm	NULL
C18	NULL
column	NULL
(	NULL
Rainin	NULL
Instruments	NULL
)	NULL
and	NULL
a	NULL
linear	NULL
gradient	NULL
over	NULL
1	NULL
h	NULL
of	NULL
0.1	NULL
%	NULL
TFA	NULL
in	NULL
water	NULL
to	NULL
0.1	NULL
%	NULL
TFA	NULL
in	NULL
70/30	NULL
acetonitrile/water	NULL
.	NULL

The	NULL
identity	NULL
was	NULL
confirmed	NULL
by	NULL
matrix-assisted	NULL
laser	NULL
desorption	NULL
ionization/time-of-flight	NULL
or	NULL
electron	NULL
spray	NULL
mass	NULL
spectrometry	NULL
.	NULL

The	NULL
peptides	NULL
were	NULL
determined	NULL
to	NULL
be	NULL
>	NULL
99	NULL
%	NULL
pure	NULL
.	NULL

The	NULL
specific	NULL
activity	NULL
of	NULL
the	NULL
Ad5	NULL
ElA	NULL
and	NULL
HPV16	NULL
E7	NULL
peptides	NULL
were	NULL
1899	NULL
cpm/nmole	NULL
and	NULL
2062	NULL
cpm/nmol	NULL
,	NULL
respectively	NULL
.	NULL

RMA-S-peptide	NULL
binding	NULL
assay	NULL
The	NULL
MHC-peptide	NULL
binding	NULL
assay	NULL
,	NULL
which	NULL
measures	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
peptide	NULL
to	NULL
bind	NULL
H2-D	NULL
``	NULL
,	NULL
was	NULL
assessed	NULL
using	NULL
the	NULL
RMA-S	NULL
cell	NULL
line	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
3	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
RMA-S	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
36	NULL
h	NULL
at	NULL
26°C	NULL
followed	NULL
by	NULL
a	NULL
4-h	NULL
incubation	NULL
with	NULL
100	NULL
ug/ml	NULL
tritiated	NULL
and	NULL
nontritiated	NULL
HPV16	NULL
E7	NULL
or	NULL
Ad5	NULL
E1A	NULL
peptides	NULL
.	NULL

Cells	NULL
were	NULL
stained	NULL
with	NULL
a	NULL
biotin-conjugated	NULL
H2-D	NULL
``	NULL
-specific	NULL
Ab	NULL
(	NULL
BD	NULL
PharMingen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
followed	NULL
by	NULL
avidin-FITC	NULL
(	NULL
BD	NULL
Biosciences	NULL
,	NULL
San	NULL
Jose	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
H2-D	NULL
``	NULL
expression	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
FACS	NULL
analysis	NULL
,	NULL
correlates	NULL
with	NULL
the	NULL
peptide	NULL
binding	NULL
affinity	NULL
.	NULL

Organ	NULL
collection	NULL
At	NULL
the	NULL
following	NULL
time	NULL
points	NULL
after	NULL
injection	NULL
,	NULL
mice	NULL
were	NULL
sacrificed	NULL
by	NULL
cervical	NULL
dislocation	NULL
:	NULL
0	NULL
,	NULL
0.5	NULL
,	NULL
1	NULL
,	NULL
2	NULL
,	NULL
4	NULL
,	NULL
8	NULL
,	NULL
24	NULL
,	NULL
48	NULL
,	NULL
72	NULL
,	NULL
120	NULL
,	NULL
168	NULL
,	NULL
and	NULL
336	NULL
h.	NULL
At	NULL
these	NULL
times	NULL
,	NULL
the	NULL
following	NULL
organs	NULL
were	NULL
collected	NULL
:	NULL
vaccine	NULL
site	NULL
,	NULL
lymph	NULL
nodes	NULL
,	NULL
spleen	NULL
,	NULL
thymus	NULL
,	NULL
heart	NULL
,	NULL
liver	NULL
,	NULL
lungs	NULL
,	NULL
kidney	NULL
,	NULL
intestines	NULL
,	NULL
brain	NULL
,	NULL
and	NULL
blood	NULL
.	NULL

Each	NULL
organ	NULL
was	NULL
frozen	NULL
at	NULL
-20°C	NULL
until	NULL
analysis	NULL
.	NULL

Whole	NULL
blood	NULL
was	NULL
hepa-rinized	NULL
and	NULL
processed	NULL
as	NULL
described	NULL
below	NULL
.	NULL

Organ	NULL
processing	NULL
All	NULL
organs	NULL
were	NULL
homogenized	NULL
in	NULL
deionized	NULL
water	NULL
at	NULL
3	NULL
ml/g	NULL
wet	NULL
weight	NULL
using	NULL
the	NULL
Polytron	NULL
PT-3100	NULL
.	NULL

A	NULL
total	NULL
of	NULL
0.3	NULL
ml	NULL
homogenate	NULL
was	NULL
digested	NULL
in	NULL
1	NULL
ml	NULL
Soluene-350	NULL
(	NULL
Packard	NULL
,	NULL
Meriden	NULL
,	NULL
CT	NULL
)	NULL
.	NULL

To	NULL
the	NULL
vaccine	NULL
site	NULL
and	NULL
organs	NULL
weighing	NULL
<	NULL
100	NULL
mg	NULL
,	NULL
0.3	NULL
ml	NULL
deionized	NULL
water	NULL
and	NULL
1	NULL
ml	NULL
Soluene-350	NULL
was	NULL
added	NULL
.	NULL

The	NULL
mixture	NULL
was	NULL
incubated	NULL
at	NULL
50°C	NULL
overnight	NULL
,	NULL
after	NULL
which	NULL
10	NULL
ml	NULL
Hionic	NULL
Fluor	NULL
scintillation	NULL
mixture	NULL
(	NULL
Packard	NULL
)	NULL
was	NULL
added	NULL
.	NULL

To	NULL
whole	NULL
blood	NULL
,	NULL
1	NULL
ml	NULL
Soluene-350	NULL
:	NULL
isopropanol	NULL
(	NULL
1:1	NULL
)	NULL
was	NULL
added	NULL
.	NULL

After	NULL
a	NULL
2-h	NULL
incubation	NULL
at	NULL
50°C	NULL
,	NULL
0.2	NULL
ml	NULL
of	NULL
30	NULL
%	NULL
H	NULL
,	NULL
O	NULL
,	NULL
was	NULL
added	NULL
.	NULL

Following	NULL
a	NULL
30-min	NULL
incubation	NULL
at	NULL
50°C	NULL
,	NULL
10	NULL
ml	NULL
Hionic	NULL
Fluor	NULL
scintillation	NULL
mixture	NULL
was	NULL
added	NULL
.	NULL

°H	NULL
content	NULL
of	NULL
all	NULL
samples	NULL
was	NULL
measured	NULL
by	NULL
a	NULL
liquid	NULL
scintillation	NULL
counter	NULL
(	NULL
Beckman	NULL
Coulter	NULL
,	NULL
Fullerton	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
cpm	NULL
were	NULL
converted	NULL
to	NULL
dpm	NULL
by	NULL
standard	NULL
quench	NULL
curves	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
measured	NULL
dpm	NULL
were	NULL
corrected	NULL
for	NULL
the	NULL
percentage	NULL
of	NULL
dpm	NULL
due	NULL
to	NULL
chemiluminescence	NULL
.	NULL

HPLC	NULL
of	NULL
homogenates	NULL
Homogenates	NULL
were	NULL
centrifuged	NULL
at	NULL
17,000	NULL
X	NULL
g	NULL
,	NULL
filtered	NULL
using	NULL
a	NULL
0.22-nm	NULL
filter	NULL
,	NULL
and	NULL
subjected	NULL
to	NULL
reverse	NULL
phase	NULL
HPLC	NULL
as	NULL
described	NULL
above	NULL
but	NULL
with	NULL
the	NULL
gradient	NULL
shortened	NULL
to	NULL
0.5	NULL
h.	NULL
Fractions	NULL
were	NULL
collected	NULL
,	NULL
and	NULL
the	NULL
radioactivity	NULL
was	NULL
measured	NULL
by	NULL
liquid	NULL
scintillation	NULL
counting	NULL
.	NULL

Analysis	NULL
of	NULL
kinetic	NULL
data	NULL
The	NULL
data	NULL
were	NULL
analyzed	NULL
as	NULL
the	NULL
mean	NULL
dpm	NULL
for	NULL
each	NULL
data	NULL
point	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
three	NULL
mice	NULL
at	NULL
each	NULL
time	NULL
point	NULL
and	NULL
each	NULL
organ	NULL
)	NULL
.	NULL

Multiple	NULL
kinetic	NULL
schemes	NULL
were	NULL
tested	NULL
;	NULL
nonlinear	NULL
fit	NULL
of	NULL
the	NULL
data	NULL
to	NULL
the	NULL
appropriate	NULL
equation	NULL
was	NULL
performed	NULL
using	NULL
the	NULL
Kaleidagraph	NULL
program	NULL
(	NULL
Abelback	NULL
software	NULL
)	NULL
.	NULL

Enzyme-linked	NULL
immunospot	NULL
(	NULL
ELISPOT	NULL
)	NULL
Spleens	NULL
were	NULL
isolated	NULL
at	NULL
defined	NULL
times	NULL
after	NULL
peptide	NULL
injection	NULL
.	NULL

Splenocytes	NULL
were	NULL
frozen	NULL
as	NULL
a	NULL
single-cell	NULL
suspension	NULL
.	NULL

Multiscreen	NULL
96-well	NULL
filtration	NULL
plates	NULL
(	NULL
Millipore	NULL
,	NULL
Bedford	NULL
,	NULL
MA	NULL
)	NULL
were	NULL
coated	NULL
with	NULL
5	NULL
pg/ml	NULL
anti-IFN-y	NULL
Ab	NULL
(	NULL
BD	NULL
PharMingen	NULL
)	NULL
overnight	NULL
.	NULL

Splenocytes	NULL
were	NULL
thawed	NULL
and	NULL
plated	NULL
in	NULL
triplicate	NULL
at	NULL
5	NULL
X	NULL
10°	NULL
and	NULL
2	NULL
X	NULL
10°	NULL
cells/well	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
30	NULL
U/ml	NULL
IL-2	NULL
and	NULL
5	NULL
ug/ml	NULL
Ad5	NULL
ElA	NULL
,	NULL
HPV16	NULL
E7	NULL
peptide	NULL
,	NULL
or	NULL
no	NULL
peptide	NULL
.	NULL

After	NULL
a	NULL
24-h	NULL
incubation	NULL
,	NULL
ELISPOT	NULL
plates	NULL
were	NULL
washed	NULL
with	NULL
PBS	NULL
containing	NULL
0.1	NULL
%	NULL
Tween	NULL
20	NULL
,	NULL
and	NULL
2.5	NULL
ug/ml	NULL
anti-IFN-y-biotin	NULL
(	NULL
BD	NULL
PharMingen	NULL
)	NULL
was	NULL
added	NULL
to	NULL
each	NULL
well	NULL
.	NULL

Plates	NULL
were	NULL
incubated	NULL
for	NULL
2	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
and	NULL
1.25	NULL
avidin-alkaline	NULL
phosphatase	NULL
(	NULL
Sigma	NULL
)	NULL
was	NULL
added	NULL
to	NULL
each	NULL
well	NULL
for	NULL
2	NULL
h.	NULL
Plates	NULL
were	NULL
washed	NULL
with	NULL
PBS	NULL
containing	NULL
0.1	NULL
%	NULL
Tween	NULL
20	NULL
followed	NULL
by	NULL
PBS	NULL
.	NULL

A	NULL
solution	NULL
of	NULL
5-bromo-4-chloro-3-indolyl	NULL
phosphate/nitroblue	NULL
tetrazolium	NULL
substrate	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
in	NULL
alkaline	NULL
phosphatase	NULL
buffer	NULL
was	NULL
added	NULL
to	NULL
each	NULL
well	NULL
and	NULL
,	NULL
after	NULL
a	NULL
15-min	NULL
incubation	NULL
,	NULL
plates	NULL
were	NULL
washed	NULL
with	NULL
deionized	NULL
water	NULL
and	NULL
air-dried	NULL
.	NULL

Spots	NULL
in	NULL
the	NULL
lower	NULL
dilution	NULL
wells	NULL
were	NULL
counted	NULL
,	NULL
averaged	NULL
,	NULL
and	NULL
subtracted	NULL
from	NULL
the	NULL
background	NULL
spots	NULL
counted	NULL
in	NULL
the	NULL
wells	NULL
stimulated	NULL
without	NULL
peptide	NULL
.	NULL

This	NULL
number	NULL
was	NULL
converted	NULL
to	NULL
the	NULL
average	NULL
number	NULL
of	NULL
CTL	NULL
precursor	NULL
cells	NULL
per	NULL
1	NULL
X	NULL
10°	NULL
cells	NULL
present	NULL
in	NULL
the	NULL
immunized	NULL
mice	NULL
.	NULL

Tetramer	NULL
analysis	NULL
C57BL/6	NULL
splenocytes	NULL
isolated	NULL
for	NULL
the	NULL
ELISPOT	NULL
were	NULL
used	NULL
for	NULL
this	NULL
assay	NULL
.	NULL

CD8	NULL
*	NULL
T	NULL
cells	NULL
were	NULL
positively	NULL
selected	NULL
using	NULL
anti-CD8	NULL
conjugated	NULL
magnetic	NULL
beads	NULL
(	NULL
Miltenyi	NULL
Biotech	NULL
,	NULL
Auburn	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

These	NULL
cells	NULL
were	NULL
stained	NULL
for	NULL
anti-CD8-FITC	NULL
(	NULL
BD	NULL
PharMingen	NULL
)	NULL
,	NULL
and	NULL
the	NULL
HPV16	NULL
E7	NULL
(	NULL
RAHYNIVTF	NULL
)	NULL
-H2-D®	NULL
tetramer	NULL
or	NULL
AdS	NULL
E1A	NULL
(	NULL
SGPSNTPPED-H2-D	NULL
``	NULL
tetramer	NULL
,	NULL
which	NULL
were	NULL
both	NULL
conjugated	NULL
with	NULL
PE	NULL
(	NULL
National	NULL
Institute	NULL
of	NULL
Allergy	NULL
and	NULL
Infectious	NULL
Diseases	NULL
tetramer	NULL
facility	NULL
,	NULL
Atlanta	NULL
,	NULL
GA	NULL
)	NULL
,	NULL
for	NULL
1	NULL
h	NULL
on	NULL
ice	NULL
.	NULL

Expression	NULL
levels	NULL
of	NULL
CD8	NULL
and	NULL
specific	NULL
TCRs	NULL
on	NULL
4	NULL
X	NULL
10°	NULL
gated	NULL
viable	NULL
cells	NULL
were	NULL
analyzed	NULL
by	NULL
FACS	NULL
.	NULL

Results	NULL
Peptide-MHC	NULL
binding	NULL
is	NULL
not	NULL
affected	NULL
after	NULL
intrinsic	NULL
labeling	NULL
with	NULL
°H	NULL
To	NULL
test	NULL
whether	NULL
the	NULL
HPV16	NULL
E7	NULL
and	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
binding	NULL
capacity	NULL
to	NULL
H2-D	NULL
``	NULL
was	NULL
altered	NULL
by	NULL
tritiation	NULL
,	NULL
a	NULL
standard	NULL
RMA-S	NULL
binding	NULL
assay	NULL
was	NULL
performed	NULL
.	NULL

The	NULL
level	NULL
of	NULL
H2-D	NULL
``	NULL
expression	NULL
on	NULL
the	NULL
cell	NULL
surface	NULL
when	NULL
RMA-S	NULL
cells	NULL
were	NULL
loaded	NULL
with	NULL
regular	NULL
peptide	NULL
or	NULL
tritiated	NULL
peptide	NULL
was	NULL
compared	NULL
by	NULL
FACS	NULL
analysis	NULL
.	NULL

No	NULL
difference	NULL
in	NULL
MHC	NULL
expression	NULL
could	NULL
be	NULL
detected	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
peptide-MHC	NULL
binding	NULL
capacity	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
intrinsic	NULL
tritiation	NULL
.	NULL

Based	NULL
on	NULL
these	NULL
data	NULL
,	NULL
the	NULL
tritiated	NULL
peptides	NULL
emulsified	NULL
in	NULL
IFA	NULL
were	NULL
compared	NULL
for	NULL
in	NULL
vivo	NULL
biodistribution	NULL
after	NULL
s.c.	NULL
injection	NULL
in	NULL
mice	NULL
.	NULL

The	NULL
tolerizing	NULL
peptide	NULL
diffuses	NULL
out	NULL
of	NULL
the	NULL
vaccine	NULL
site	NULL
more	NULL
rapidly	NULL
than	NULL
the	NULL
T	NULL
cell-activating	NULL
peptide	NULL
The	NULL
tritium	NULL
content	NULL
of	NULL
the	NULL
vaccine	NULL
site	NULL
was	NULL
assessed	NULL
at	NULL
different	NULL
times	NULL
after	NULL
injection	NULL
with	NULL
300	NULL
ug	NULL
*H-labeled	NULL
AdS	NULL
E1A	NULL
or	NULL
HPV16	NULL
E7	NULL
peptide	NULL
emulsified	NULL
in	NULL
IFA	NULL
.	NULL

Fig	NULL
.	NULL

24	NULL
shows	NULL
that	NULL
,	NULL
3	NULL
h	NULL
after	NULL
injection	NULL
,	NULL
the	NULL
tolerizing	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
started	NULL
to	NULL
egress	NULL
from	NULL
the	NULL
vaccine	NULL
site	NULL
,	NULL
whereas	NULL
increased	NULL
egression	NULL
of	NULL
the	NULL
activating	NULL
HPV16	NULL
E7	NULL
peptide	NULL
started	NULL
10	NULL
h	NULL
after	NULL
injection	NULL
.	NULL

Furthermore	NULL
,	NULL
egression	NULL
of	NULL
the	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
halted	NULL
after	NULL
72	NULL
h	NULL
,	NULL
and	NULL
egression	NULL
of	NULL
the	NULL
HPV16	NULL
E7	NULL
peptide	NULL
stopped	NULL
after	NULL
200	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

Comparison	NULL
of	NULL
the	NULL
egression	NULL
rate	NULL
constants	NULL
(	NULL
K	NULL
,	NULL
)	NULL
of	NULL
the	NULL
two	NULL
peptides	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
showed	NULL
that	NULL
the	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
egressed	NULL
from	NULL
the	NULL
Ag	NULL
depot	NULL
2.7	NULL
times	NULL
faster	NULL
than	NULL
the	NULL
HPV16	NULL
E7	NULL
peptide	NULL
.	NULL

The	NULL
tolerizing	NULL
Ad5	NULL
EIA	NULL
peptide	NULL
reaches	NULL
its	NULL
maximum	NULL
concentration	NULL
in	NULL
all	NULL
organs	NULL
earlier	NULL
and	NULL
declines	NULL
in	NULL
concentration	NULL
faster	NULL
than	NULL
the	NULL
activating	NULL
HPV	NULL
16	NULL
E7	NULL
peptide	NULL
.	NULL

To	NULL
establish	NULL
the	NULL
pharmacokinetic	NULL
behavior	NULL
of	NULL
the	NULL
two	NULL
peptides	NULL
with	NULL
respect	NULL
to	NULL
organ	NULL
distribution	NULL
,	NULL
several	NULL
organs	NULL
were	NULL
analyzed	NULL
for	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
A	NULL
9	NULL
O	NULL
sd	NULL
o	NULL
$	NULL
9.—	NULL
t	NULL
81	NULL
0	NULL
ged	NULL
l=l	NULL
93	NULL
o	NULL
4	NULL
.	NULL

10°	NULL
ao	NULL
``	NULL
102	NULL
)	NULL
108	NULL
aot	NULL
H2-D	NULL
``	NULL
°	NULL
&	NULL
a	NULL
ag	NULL
§	NULL
set	NULL
28	NULL
;	NULL
0	NULL
de	NULL
:	NULL
o	NULL
|	NULL
<	NULL
04	NULL
®	NULL
ao	NULL
)	NULL
102	NULL
10°	NULL
aot	NULL
H2-D°	NULL
FIGURE	NULL
1	NULL
.	NULL

Tritiation	NULL
of	NULL
peptides	NULL
does	NULL
not	NULL
alter	NULL
binding	NULL
to	NULL
H2-D	NULL
``	NULL
.	NULL

RMA-S	NULL
cells	NULL
were	NULL
loaded	NULL
with	NULL
tritiated	NULL
or	NULL
nontritiated	NULL
CTL	NULL
peptides	NULL
,	NULL
and	NULL
the	NULL
MHC	NULL
class	NULL
I	NULL
(	NULL
H2-D	NULL
``	NULL
)	NULL
expression	NULL
was	NULL
compared	NULL
by	NULL
FACS	NULL
analysis	NULL
for	NULL
the	NULL
HPV16	NULL
E7	NULL
peptide	NULL
(	NULL
A	NULL
)	NULL
and	NULL
the	NULL
AdS	NULL
E1A	NULL
peptide	NULL
(	NULL
B	NULL
)	NULL
.	NULL

The	NULL
thin	NULL
line	NULL
represents	NULL
RMA-S	NULL
cells	NULL
without	NULL
peptide	NULL
,	NULL
the	NULL
bold	NULL
line	NULL
represents	NULL
RMA-S	NULL
cells	NULL
loaded	NULL
with	NULL
tritiated	NULL
peptide	NULL
,	NULL
and	NULL
the	NULL
dotted	NULL
line	NULL
represents	NULL
RMA-S	NULL
cells	NULL
loaded	NULL
with	NULL
nontritiated	NULL
peptide	NULL
.	NULL

as	NULL
2	NULL
their	NULL
tritium	NULL
content	NULL
at	NULL
different	NULL
points	NULL
in	NULL
time	NULL
,	NULL
and	NULL
influx	NULL
and	NULL
egression	NULL
parameters	NULL
were	NULL
calculated	NULL
.	NULL

In	NULL
four	NULL
independent	NULL
experiments	NULL
with	NULL
three	NULL
mice	NULL
per	NULL
time	NULL
point	NULL
,	NULL
the	NULL
pharmacokinetic	NULL
behavior	NULL
of	NULL
each	NULL
individual	NULL
peptide	NULL
in	NULL
all	NULL
organs	NULL
was	NULL
found	NULL
to	NULL
be	NULL
very	NULL
consistent	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
pharmacokinetics	NULL
in	NULL
lymphoid	NULL
organs	NULL
,	NULL
in	NULL
which	NULL
induction	NULL
of	NULL
the	NULL
CTL	NULL
response	NULL
should	NULL
take	NULL
place	NULL
,	NULL
spleen	NULL
,	NULL
thymus	NULL
,	NULL
and	NULL
lymph	NULL
nodes	NULL
were	NULL
analyzed	NULL
for	NULL
their	NULL
tritium	NULL
content	NULL
.	NULL

Fig	NULL
.	NULL

3	NULL
shows	NULL
the	NULL
pharmacokinetics	NULL
of	NULL
both	NULL
peptides	NULL
in	NULL
the	NULL
spleen	NULL
.	NULL

The	NULL
maximum	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
concentration	NULL
in	NULL
the	NULL
spleen	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
the	NULL
HPV16	NULL
E7	NULL
peptide	NULL
con-centration	NULL
;	NULL
however	NULL
,	NULL
the	NULL
maximum	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
concentration	NULL
was	NULL
reached	NULL
after	NULL
~10	NULL
h	NULL
,	NULL
and	NULL
it	NULL
declined	NULL
to	NULL
an	NULL
equilibrium	NULL
after	NULL
~100	NULL
h.	NULL
The	NULL
HPV16	NULL
E7	NULL
peptide	NULL
reached	NULL
the	NULL
maximum	NULL
concentration	NULL
in	NULL
the	NULL
spleen	NULL
~140	NULL
h	NULL
after	NULL
injection	NULL
,	NULL
and	NULL
its	NULL
concentration	NULL
had	NULL
not	NULL
equilibrated	NULL
to	NULL
baseline	NULL
levels	NULL
as	NULL
late	NULL
as	NULL
350	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

Identical	NULL
peptide	NULL
concentration	NULL
and	NULL
kinetics	NULL
were	NULL
detected	NULL
in	NULL
5	NULL
10°	NULL
14105	NULL
Fe	NULL
T	NULL
g.	NULL
410°	NULL
33105	NULL
g	NULL
a	NULL
E	NULL
W	NULL
3	NULL
495	NULL
32105	NULL
E	NULL
210°	NULL
59	NULL
71	NULL
105	NULL
0.1	NULL
1	NULL
10	NULL
~	NULL
100	NULL
1000	NULL
Time	NULL
(	NULL
h	NULL
)	NULL
7153	NULL
the	NULL
thymus	NULL
as	NULL
indicated	NULL
in	NULL
Table	NULL
I.	NULL
Tritium	NULL
concentration	NULL
in	NULL
pooled	NULL
lymph	NULL
nodes	NULL
was	NULL
also	NULL
measured	NULL
but	NULL
never	NULL
attained	NULL
levels	NULL
above	NULL
background	NULL
.	NULL

This	NULL
is	NULL
most	NULL
likely	NULL
due	NULL
to	NULL
the	NULL
extremely	NULL
small	NULL
size	NULL
of	NULL
these	NULL
organs	NULL
,	NULL
resulting	NULL
in	NULL
an	NULL
undetectable	NULL
tritium	NULL
concentration	NULL
.	NULL

Simultaneous	NULL
adoptive	NULL
transfer	NULL
of	NULL
AdS	NULL
E1A-specific	NULL
CTLs	NULL
and	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
injection	NULL
into	NULL
nude	NULL
mice	NULL
resulted	NULL
in	NULL
severe	NULL
lung	NULL
destruction	NULL
16	NULL
h	NULL
after	NULL
injection	NULL
(	NULL
4	NULL
)	NULL
.	NULL

The	NULL
suggested	NULL
hypothesis	NULL
was	NULL
that	NULL
this	NULL
could	NULL
be	NULL
attributed	NULL
to	NULL
a	NULL
rapid	NULL
influx	NULL
of	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
in	NULL
the	NULL
lungs	NULL
.	NULL

To	NULL
test	NULL
this	NULL
hypothesis	NULL
,	NULL
pharmacokinetics	NULL
of	NULL
both	NULL
peptides	NULL
were	NULL
measured	NULL
in	NULL
the	NULL
lungs	NULL
and	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

The	NULL
kinetics	NULL
of	NULL
both	NULL
HPV16	NULL
E7	NULL
and	NULL
AdS	NULL
ElA	NULL
peptides	NULL
in	NULL
the	NULL
lungs	NULL
are	NULL
very	NULL
similar	NULL
to	NULL
those	NULL
detected	NULL
in	NULL
the	NULL
spleen	NULL
in	NULL
that	NULL
maximum	NULL
peptide	NULL
concentrations	NULL
are	NULL
reached	NULL
at	NULL
10	NULL
and	NULL
170	NULL
h	NULL
after	NULL
Ad5	NULL
ElA	NULL
or	NULL
HPV16	NULL
E7	NULL
peptide	NULL
injection	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
,	NULL
due	NULL
to	NULL
the	NULL
large	NULL
difference	NULL
(	NULL
~36-fold	NULL
)	NULL
in	NULL
influx	NULL
between	NULL
both	NULL
peptides	NULL
into	NULL
the	NULL
lungs	NULL
as	NULL
represented	NULL
by	NULL
the	NULL
slope	NULL
of	NULL
the	NULL
curves	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
HPV16	NULL
E7	NULL
peptide	NULL
persists	NULL
in	NULL
the	NULL
lungs	NULL
at	NULL
least	NULL
100	NULL
h	NULL
longer	NULL
then	NULL
the	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
,	NULL
while	NULL
both	NULL
peptides	NULL
spread	NULL
to	NULL
and	NULL
egress	NULL
from	NULL
all	NULL
organs	NULL
with	NULL
similar	NULL
kinetics	NULL
,	NULL
each	NULL
individual	NULL
peptide	NULL
does	NULL
so	NULL
with	NULL
distinct	NULL
kinetics	NULL
.	NULL

This	NULL
difference	NULL
in	NULL
kinetic	NULL
behavior	NULL
between	NULL
these	NULL
two	NULL
peptides	NULL
depends	NULL
on	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
peptide	NULL
rather	NULL
than	NULL
that	NULL
of	NULL
the	NULL
organ	NULL
.	NULL

Intact	NULL
peptides	NULL
can	NULL
be	NULL
detected	NULL
24	NULL
h	NULL
after	NULL
injection	NULL
To	NULL
determine	NULL
whether	NULL
the	NULL
tritium	NULL
measured	NULL
in	NULL
the	NULL
different	NULL
organs	NULL
originated	NULL
from	NULL
intact	NULL
peptide	NULL
,	NULL
free	NULL
amino	NULL
acids	NULL
,	NULL
or	NULL
other	NULL
degradation	NULL
products	NULL
,	NULL
homogenates	NULL
of	NULL
most	NULL
organs	NULL
obtained	NULL
24	NULL
h	NULL
after	NULL
injection	NULL
were	NULL
analyzed	NULL
by	NULL
reversed	NULL
phase	NULL
HPLC	NULL
analysis	NULL
and	NULL
compared	NULL
with	NULL
pure	NULL
synthetic	NULL
tritiated	NULL
peptide	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

With	NULL
the	NULL
exception	NULL
of	NULL
the	NULL
intestines	NULL
,	NULL
the	NULL
tritium	NULL
label	NULL
eluted	NULL
from	NULL
all	NULL
organs	NULL
in	NULL
the	NULL
same	NULL
fraction	NULL
as	NULL
intact	NULL
synthetic	NULL
peptide	NULL
(	NULL
fraction	NULL
17	NULL
and	NULL
18	NULL
for	NULL
the	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
and	NULL
fraction	NULL
23	NULL
for	NULL
the	NULL
HPV16	NULL
E7	NULL
pep-tide	NULL
)	NULL
,	NULL
demonstrating	NULL
that	NULL
the	NULL
label	NULL
was	NULL
still	NULL
contained	NULL
within	NULL
intact	NULL
peptide	NULL
.	NULL

In	NULL
the	NULL
intestines	NULL
,	NULL
the	NULL
label	NULL
eluted	NULL
in	NULL
the	NULL
void	NULL
volume	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
peptide	NULL
had	NULL
been	NULL
degraded	NULL
to	NULL
amino	NULL
acids	NULL
or	NULL
other	NULL
polar	NULL
products	NULL
.	NULL

The	NULL
kinetics	NULL
of	NULL
Ad5	NULL
E1A-	NULL
and	NULL
HPV16	NULL
E7-specific	NULL
CTL	NULL
induction	NULL
corresponds	NULL
to	NULL
the	NULL
peptide	NULL
kinetics	NULL
The	NULL
previous	NULL
data	NULL
indicate	NULL
a	NULL
clear	NULL
difference	NULL
in	NULL
the	NULL
kinetics	NULL
of	NULL
the	NULL
tolerizing	NULL
(	NULL
Ad5	NULL
E1A	NULL
)	NULL
and	NULL
the	NULL
activating	NULL
peptides	NULL
(	NULL
HPV16	NULL
E7	NULL
)	NULL
.	NULL

However	NULL
,	NULL
these	NULL
differences	NULL
may	NULL
not	NULL
be	NULL
the	NULL
cause	NULL
of	NULL
the	NULL
observed	NULL
functional	NULL
I	NULL
I	NULL
T	NULL
I	NULL
T	NULL
``	NULL
T	NULL
T	NULL
]	NULL
51055	NULL
44105	NULL
€	NULL
de	NULL
ags	NULL
2	NULL
o	NULL
.	NULL

5	NULL
BN	NULL
g	NULL
+1	NULL
``	NULL
INT	NULL
1310	NULL
3	NULL
4	NULL
``	NULL
O	NULL
4	NULL
E	NULL
B	NULL
3105	NULL
}	NULL
}	NULL
42105	NULL
i	NULL
~	NULL
__	NULL
E	NULL
2	NULL
105	NULL
hu	NULL
cod	NULL
}	NULL
1	NULL
108	NULL
0	NULL
50	NULL
100	NULL
150	NULL
200	NULL
250	NULL
300	NULL
350	NULL
Time	NULL
(	NULL
h	NULL
)	NULL
FIGURE	NULL
2	NULL
.	NULL

The	NULL
tolerizing	NULL
AdS	NULL
E1A	NULL
peptide	NULL
egresses	NULL
from	NULL
the	NULL
vaccine	NULL
site	NULL
faster	NULL
than	NULL
the	NULL
activating	NULL
HPV16	NULL
E7	NULL
peptide	NULL
.	NULL

Intact	NULL
vaccine	NULL
sites	NULL
were	NULL
collected	NULL
at	NULL
different	NULL
times	NULL
after	NULL
peptide	NULL
injection	NULL
,	NULL
and	NULL
°H	NULL
was	NULL
measured	NULL
.	NULL

Curve	NULL
fit	NULL
was	NULL
performed	NULL
according	NULL
to	NULL
the	NULL
following	NULL
equation	NULL
:	NULL
A	NULL
-	NULL
A	NULL
,	NULL
,	NULL
=	NULL
eq	NULL
(	NULL
Acq	NULL
-	NULL
Ag	NULL
)	NULL
e~	NULL
~*	NULL
,	NULL
where	NULL
A	NULL
is	NULL
the	NULL
radioactivity	NULL
in	NULL
the	NULL
vaccine	NULL
site	NULL
,	NULL
and	NULL
A	NULL
,	NULL
and	NULL
A.	NULL
,	NULL
are	NULL
parameters	NULL
representing	NULL
the	NULL
initial	NULL
radioactivity	NULL
and	NULL
the	NULL
final	NULL
(	NULL
``	NULL
equilibrium	NULL
``	NULL
)	NULL
radioactivity	NULL
.	NULL

Curve	NULL
fits	NULL
are	NULL
shown	NULL
on	NULL
a	NULL
logaritmic	NULL
(	NULL
4	NULL
)	NULL
and	NULL
a	NULL
linear	NULL
(	NULL
B	NULL
)	NULL
scale	NULL
to	NULL
enable	NULL
data	NULL
analysis	NULL
at	NULL
different	NULL
times	NULL
after	NULL
peptide	NULL
injection	NULL
.	NULL

The	NULL
SEM	NULL
has	NULL
been	NULL
included	NULL
for	NULL
each	NULL
time	NULL
point	NULL
.	NULL

This	NULL
is	NULL
one	NULL
representative	NULL
experiment	NULL
of	NULL
four	NULL
independent	NULL
experiments	NULL
performed	NULL
.	NULL

Squares	NULL
represent	NULL
the	NULL
HPV16	NULL
E7	NULL
peptide	NULL
,	NULL
and	NULL
circles	NULL
represent	NULL
the	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
7154	NULL
IN	NULL
VIVO	NULL
KINETICS	NULL
OF	NULL
A	NULL
TOLERIZING	NULL
AND	NULL
AN	NULL
ACTIVATING	NULL
PEPTIDE	NULL
Table	NULL
I	NULL
.	NULL

-	NULL
Peptide	NULL
pharmacokinetics	NULL
and	NULL
organ	NULL
distribution	NULL
``	NULL
Rate	NULL
Constant	NULL
Rate	NULL
Constant	NULL
Organ	NULL
Peptide	NULL
Cras	NULL
``	NULL
Truax	NULL
``	NULL
(	NULL
K	NULL
)	NULL
*	NULL
(	NULL
K	NULL
)	NULL
°	NULL
Vaccine	NULL
site	NULL
Ad5	NULL
E1A	NULL
0	NULL
0	NULL
NA	NULL
0.0577	NULL
HPV16	NULL
E7	NULL
0	NULL
0	NULL
NA	NULL
0.0208	NULL
Lungs	NULL
Ad5	NULL
E1A	NULL
0.35	NULL
15	NULL
0.2735	NULL
0.01132	NULL
HPV16	NULL
E7	NULL
0.37	NULL
160	NULL
0.0075952	NULL
0.0030781	NULL
Spleen	NULL
Ad5	NULL
E1A	NULL
0.17	NULL
15	NULL
0.023366	NULL
0.23203	NULL
HPV16	NULL
E7	NULL
0.22	NULL
160	NULL
0.0022458	NULL
0.0051557	NULL
Thymus	NULL
Ad5	NULL
E1A	NULL
0.24	NULL
15	NULL
0.011814	NULL
0.25661	NULL
HPV16	NULL
E7	NULL
0.2	NULL
160	NULL
0.0034155	NULL
0.001901	NULL
Brain	NULL
Ad5	NULL
E1A	NULL
0.69	NULL
10	NULL
0.3424	NULL
0.0084	NULL
HPV16	NULL
E7	NULL
0.76	NULL
105	NULL
0.0048	NULL
0.0029	NULL
Heart	NULL
Ad5	NULL
E1A	NULL
0.25	NULL
20	NULL
0.3401	NULL
0.0006	NULL
HPV16	NULL
E7	NULL
0.3	NULL
160	NULL
0.0068	NULL
0.0042	NULL
Kidney	NULL
Ad5	NULL
E1A	NULL
0.62	NULL
20	NULL
0.2052	NULL
0.0055	NULL
HPV16	NULL
E7	NULL
0.9	NULL
160	NULL
0.0092	NULL
0.0038	NULL
Intestines	NULL
Ad5	NULL
E1A	NULL
8	NULL
20	NULL
0.0924	NULL
0.014	NULL
HPV16	NULL
E7	NULL
6.6	NULL
160	NULL
0.0049	NULL
0.0019	NULL
Liver	NULL
Ad5	NULL
E1A	NULL
2	NULL
15	NULL
0.4054	NULL
0.0054	NULL
HPV16	NULL
E7	NULL
3	NULL
160	NULL
0.0072	NULL
0.0033	NULL
Blood	NULL
Ad5	NULL
E1A	NULL
5	NULL
15	NULL
0.2551	NULL
0.0097	NULL
HPV16	NULL
E7	NULL
4.2	NULL
160	NULL
0.0103	NULL
0.003	NULL
*	NULL
This	NULL
is	NULL
a	NULL
representative	NULL
experiment	NULL
(	NULL
7	NULL
=	NULL
4	NULL
)	NULL
in	NULL
which	NULL
three	NULL
mice	NULL
per	NULL
time	NULL
point	NULL
per	NULL
peptide	NULL
were	NULL
sacrificed	NULL
to	NULL
obtain	NULL
tritium	NULL
content	NULL
of	NULL
different	NULL
organs	NULL
.	NULL

*	NULL
C	NULL
...	NULL
,	NULL
refers	NULL
to	NULL
the	NULL
maximal	NULL
peptide	NULL
concentration	NULL
reached	NULL
as	NULL
a	NULL
percentage	NULL
of	NULL
total	NULL
injected	NULL
peptide	NULL
.	NULL

°	NULL
T	NULL
...	NULL
..	NULL
refers	NULL
to	NULL
the	NULL
time	NULL
(	NULL
h	NULL
)	NULL
at	NULL
which	NULL
the	NULL
C	NULL
...	NULL
...	NULL
is	NULL
reached	NULL
.	NULL

``	NULL
Rate	NULL
constant	NULL
(	NULL
h	NULL
'	NULL
)	NULL
into	NULL
the	NULL
organ	NULL
.	NULL

This	NULL
is	NULL
indicated	NULL
by	NULL
the	NULL
slope	NULL
of	NULL
the	NULL
curve	NULL
in	NULL
the	NULL
linear	NULL
area	NULL
;	NULL
a	NULL
steep	NULL
curve	NULL
and	NULL
therefore	NULL
a	NULL
high	NULL
rate	NULL
constant	NULL
indicates	NULL
a	NULL
high	NULL
influx	NULL
of	NULL
the	NULL
peptide	NULL
into	NULL
the	NULL
organ	NULL
.	NULL

®	NULL
Rate	NULL
constant	NULL
(	NULL
h	NULL
~	NULL
'	NULL
)	NULL
out	NULL
of	NULL
the	NULL
organ	NULL
.	NULL

*The	NULL
rate	NULL
constant	NULL
into	NULL
the	NULL
organ	NULL
is	NULL
not	NULL
applicable	NULL
(	NULL
NA	NULL
)	NULL
for	NULL
the	NULL
vaccine	NULL
site	NULL
.	NULL

differences	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
a	NULL
CTL	NULL
response	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
assessed	NULL
the	NULL
kinetics	NULL
of	NULL
the	NULL
Ad5	NULL
E1A-	NULL
and	NULL
HPV16	NULL
E7-specific	NULL
CTL	NULL
responses	NULL
after	NULL
peptide	NULL
injection	NULL
.	NULL

Mice	NULL
were	NULL
immunized	NULL
s.c.	NULL
with	NULL
100	NULL
ug	NULL
Ad5	NULL
ElA	NULL
or	NULL
HPV16	NULL
E7	NULL
peptide	NULL
in	NULL
IFA	NULL
.	NULL

At	NULL
defined	NULL
times	NULL
after	NULL
peptide	NULL
injection	NULL
,	NULL
splenocytes	NULL
were	NULL
isolated	NULL
and	NULL
the	NULL
number	NULL
of	NULL
Ad5	NULL
E1A-	NULL
and	NULL
HPV16	NULL
E7-specific	NULL
CTLs	NULL
was	NULL
measured	NULL
by	NULL
ELISPOT	NULL
.	NULL

Fig	NULL
.	NULL

6A	NULL
shows	NULL
that	NULL
an	NULL
increase	NULL
in	NULL
HPV16	NULL
E7-specific	NULL
CTL	NULL
precursors	NULL
was	NULL
observed	NULL
72	NULL
h	NULL
after	NULL
peptide	NULL
injection	NULL
.	NULL

The	NULL
CTL	NULL
response	NULL
peaked	NULL
at	NULL
120-168	NULL
h	NULL
after	NULL
peptide	NULL
injection	NULL
and	NULL
returned	NULL
to	NULL
the	NULL
original	NULL
CTL	NULL
level	NULL
after	NULL
2	NULL
wk	NULL
.	NULL

A	NULL
similar	NULL
pattern	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
HPV16	NULL
E7-H2-D	NULL
``	NULL
tetramer	NULL
analysis	NULL
performed	NULL
at	NULL
the	NULL
same	NULL
time	NULL
points	NULL
after	NULL
peptide	NULL
injection	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

As	NULL
observed	NULL
in	NULL
the	NULL
ELISPOT	NULL
assay	NULL
,	NULL
the	NULL
1000	NULL
t	NULL
pr	NULL
t	NULL
1200	NULL
E1A	NULL
(	NULL
DPM	NULL
)	NULL
(	NULL
Wad	NULL
)	NULL
23	NULL
c	NULL
0	NULL
0.1	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
Time	NULL
(	NULL
h	NULL
)	NULL
number	NULL
of	NULL
HPV16	NULL
E7-specific	NULL
CTLs	NULL
increased	NULL
120	NULL
h	NULL
after	NULL
peptide	NULL
injection	NULL
and	NULL
declined	NULL
2	NULL
wk	NULL
after	NULL
injection	NULL
.	NULL

The	NULL
E7-specific	NULL
CTL	NULL
kinetics	NULL
corresponds	NULL
strongly	NULL
with	NULL
E7	NULL
peptide	NULL
kinetics	NULL
,	NULL
which	NULL
also	NULL
showed	NULL
a	NULL
peak	NULL
in	NULL
E7	NULL
peptide	NULL
concentration	NULL
between	NULL
120	NULL
and	NULL
168	NULL
h	NULL
after	NULL
injection	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
a	NULL
significant	NULL
Ad5	NULL
E1A-specific	NULL
CTL	NULL
response	NULL
was	NULL
not	NULL
detected	NULL
by	NULL
ELISPOT	NULL
(	NULL
Fig	NULL
.	NULL

6C	NULL
)	NULL
or	NULL
by	NULL
Ad5	NULL
E1A-	NULL
H2-D	NULL
``	NULL
tetramer	NULL
staining	NULL
(	NULL
Fig	NULL
.	NULL

61	NULL
)	NULL
.	NULL

The	NULL
positive	NULL
control	NULL
(	NULL
spleno-cytes	NULL
isolated	NULL
from	NULL
mice	NULL
immunized	NULL
with	NULL
irradiated	NULL
tumor	NULL
cells	NULL
expressing	NULL
the	NULL
Ad5	NULL
E1A	NULL
protein	NULL
)	NULL
showed	NULL
a	NULL
significant	NULL
induction	NULL
of	NULL
Ad5	NULL
E1	NULL
A-specific	NULL
CTLs	NULL
by	NULL
tetramer	NULL
staining	NULL
(	NULL
Fig	NULL
.	NULL

6D	NULL
)	NULL
.	NULL

This	NULL
proves	NULL
that	NULL
Ad5	NULL
E1	NULL
A-specific	NULL
CTLs	NULL
can	NULL
be	NULL
induced	NULL
,	NULL
but	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
in	NULL
IFA	NULL
did	NULL
not	NULL
induce	NULL
Ad5	NULL
E1A-specific	NULL
CTLs	NULL
.	NULL

1000	NULL
_	NULL
,	NULL
800	NULL
m	NULL
E	NULL
~	NULL
&	NULL
soo	NULL
g	NULL
4	NULL
400	NULL
3	NULL
L	NULL
200	NULL
0	NULL
R	NULL
1	NULL
1	NULL
spree	NULL
.	NULL

0	NULL
0	NULL
50	NULL
100	NULL
150	NULL
200	NULL
250	NULL
300	NULL
350	NULL
Time	NULL
(	NULL
h	NULL
)	NULL
FIGURE	NULL
3	NULL
.	NULL

The	NULL
tolerizing	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
appears	NULL
in	NULL
and	NULL
disappears	NULL
from	NULL
the	NULL
spleen	NULL
significantly	NULL
earlier	NULL
than	NULL
the	NULL
activating	NULL
HPV16	NULL
E7	NULL
peptide	NULL
.	NULL

The	NULL
spleen	NULL
was	NULL
collected	NULL
at	NULL
different	NULL
times	NULL
after	NULL
injection	NULL
,	NULL
and	NULL
°H	NULL
was	NULL
measured	NULL
at	NULL
different	NULL
times	NULL
after	NULL
injection	NULL
.	NULL

For	NULL
the	NULL
consecutive	NULL
first	NULL
order	NULL
reactions	NULL
A-	NULL
>	NULL
B-	NULL
>	NULL
C	NULL
,	NULL
the	NULL
concentration	NULL
of	NULL
B	NULL
is	NULL
given	NULL
by	NULL
the	NULL
equation	NULL
:	NULL
B	NULL
=	NULL
Apk	NULL
;	NULL
/	NULL
k	NULL
,	NULL
-	NULL
k	NULL
,	NULL
(	NULL
e*	NULL
-	NULL
e~*	NULL
)	NULL
,	NULL
where	NULL
k	NULL
;	NULL
and	NULL
k	NULL
,	NULL
are	NULL
rate	NULL
constants	NULL
for	NULL
the	NULL
two	NULL
reactions	NULL
.	NULL

The	NULL
radioactivity	NULL
deviated	NULL
from	NULL
this	NULL
equation	NULL
at	NULL
later	NULL
time	NULL
points	NULL
,	NULL
because	NULL
it	NULL
returned	NULL
to	NULL
slightly	NULL
above	NULL
the	NULL
original	NULL
baseline	NULL
.	NULL

Accordingly	NULL
,	NULL
the	NULL
scheme	NULL
was	NULL
modified	NULL
to	NULL
take	NULL
this	NULL
into	NULL
account	NULL
,	NULL
resulting	NULL
in	NULL
the	NULL
following	NULL
equation	NULL
:	NULL
radioactivity	NULL
=	NULL
ae	NULL
**	NULL
-	NULL
be~***	NULL
+	NULL
c	NULL
,	NULL
in	NULL
which	NULL
a	NULL
#	NULL
b	NULL
,	NULL
and	NULL
a	NULL
,	NULL
b	NULL
,	NULL
and	NULL
c	NULL
are	NULL
aggregated	NULL
kinetic	NULL
parameters	NULL
including	NULL
terms	NULL
for	NULL
rate	NULL
constants	NULL
and	NULL
apparent	NULL
pool	NULL
sizes	NULL
.	NULL

Curve	NULL
fits	NULL
are	NULL
shown	NULL
on	NULL
a	NULL
logaritmic	NULL
(	NULL
A	NULL
)	NULL
and	NULL
a	NULL
linear	NULL
(	NULL
B	NULL
)	NULL
scale	NULL
to	NULL
enable	NULL
data	NULL
analysis	NULL
at	NULL
different	NULL
times	NULL
after	NULL
peptide	NULL
injection	NULL
.	NULL

This	NULL
is	NULL
one	NULL
representative	NULL
experiment	NULL
of	NULL
four	NULL
independent	NULL
experiments	NULL
performed	NULL
.	NULL

The	NULL
SEM	NULL
has	NULL
been	NULL
included	NULL
for	NULL
each	NULL
time	NULL
point	NULL
.	NULL

Squares	NULL
represent	NULL
the	NULL
HPV16	NULL
E7	NULL
peptide	NULL
,	NULL
and	NULL
circles	NULL
represent	NULL
the	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
1400	NULL
r	NULL
r	NULL
v	NULL
1200	NULL
1200	NULL
}	NULL
-~	NULL
®	NULL
11000	NULL
#	NULL
74	NULL
m'\	NULL
'	NULL
/'\	NULL
<	NULL
1000	NULL
}	NULL
/a	NULL
f	NULL
S	NULL
/	NULL
j	NULL
|_	NULL
{	NULL
soo	NULL
8	NULL
2	NULL
soo	NULL
}	NULL
4	NULL
C	NULL
<	NULL
/	NULL
1	NULL
jeoo	NULL
&	NULL
d	NULL
;	NULL
600f	NULL
/	NULL
700034	NULL
Jaco	NULL
400	NULL
}	NULL
1	NULL
/*	NULL
y	NULL
``	NULL
,	NULL
___	NULL
*	NULL
1200	NULL
o	NULL
aoa	NULL
at	NULL
1	NULL
P	NULL
aun	NULL
‘	NULL
0	NULL
0.1	NULL
1	NULL
10	NULL
_	NULL
100	NULL
_	NULL
1000	NULL
Time	NULL
(	NULL
h	NULL
)	NULL
7155	NULL
1400	NULL
5	NULL
1200	NULL
©	NULL
1200	NULL
|/	NULL
you	NULL
a	NULL
:	NULL
11000	NULL
a	NULL
f	NULL
”	NULL
z	NULL
®	NULL
Ta	NULL
210004	NULL
\/	NULL
n	NULL
{	NULL
soo	NULL
m	NULL
I	NULL
.	NULL

$	NULL
>	NULL
am	NULL
<	NULL
800	NULL
“	NULL
4	NULL
,	NULL
``	NULL
sa	NULL
.	NULL

*~	NULL
-	NULL
}	NULL
g0o	NULL
E	NULL
u	NULL
soo	NULL
}	NULL
/	NULL
Nypoll	NULL
No	NULL
5	NULL
--	NULL
--	NULL
--	NULL
-	NULL
£	NULL
]	NULL
400	NULL
400	NULL
}	NULL
/	NULL
20°F	NULL
1200	NULL
o	NULL
:	NULL
o	NULL
1	NULL
1	NULL
1	NULL
1	NULL
1	NULL
0	NULL
100	NULL
150	NULL
200	NULL
250	NULL
300	NULL
350	NULL
Time	NULL
(	NULL
h	NULL
)	NULL
FIGURE	NULL
4	NULL
.	NULL

The	NULL
tolerizing	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
appears	NULL
and	NULL
disappears	NULL
in	NULL
the	NULL
lungs	NULL
significantly	NULL
earlier	NULL
than	NULL
the	NULL
activating	NULL
HPV16	NULL
E7	NULL
peptide	NULL
.	NULL

Lungs	NULL
were	NULL
collected	NULL
at	NULL
different	NULL
times	NULL
after	NULL
injection	NULL
,	NULL
and	NULL
°H	NULL
was	NULL
measured	NULL
.	NULL

The	NULL
same	NULL
kinetics	NULL
as	NULL
mentioned	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
were	NULL
applied	NULL
to	NULL
tritium	NULL
data	NULL
measured	NULL
in	NULL
the	NULL
lungs	NULL
.	NULL

Curve	NULL
fits	NULL
are	NULL
shown	NULL
on	NULL
a	NULL
logarithmic	NULL
(	NULL
A	NULL
)	NULL
and	NULL
a	NULL
linear	NULL
(	NULL
B	NULL
)	NULL
scale	NULL
to	NULL
enable	NULL
data	NULL
analysis	NULL
at	NULL
different	NULL
times	NULL
after	NULL
peptide	NULL
injection	NULL
.	NULL

This	NULL
is	NULL
one	NULL
representative	NULL
experiment	NULL
of	NULL
four	NULL
independent	NULL
experiments	NULL
performed	NULL
.	NULL

The	NULL
SEM	NULL
has	NULL
been	NULL
included	NULL
for	NULL
each	NULL
time	NULL
point	NULL
.	NULL

Squares	NULL
represent	NULL
the	NULL
HPV16	NULL
E7	NULL
peptide	NULL
,	NULL
and	NULL
circles	NULL
represent	NULL
the	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
.	NULL

Ad5	NULL
EIA-specific	NULL
CTLs	NULL
are	NULL
deleted	NULL
within	NULL
24	NULL
h	NULL
after	NULL
Ad5	NULL
EIA	NULL
peptide	NULL
injection	NULL
The	NULL
absence	NULL
of	NULL
an	NULL
Ad5	NULL
E1A-specific	NULL
CTL	NULL
response	NULL
after	NULL
AdS	NULL
E1A	NULL
peptide	NULL
injection	NULL
could	NULL
be	NULL
due	NULL
to	NULL
a	NULL
functional	NULL
or	NULL
physical	NULL
deletion	NULL
of	NULL
Ad5	NULL
E1	NULL
A-specific	NULL
CTLs	NULL
.	NULL

To	NULL
test	NULL
this	NULL
,	NULL
C57BL/6	NULL
mice	NULL
were	NULL
preimmunized	NULL
twice	NULL
with	NULL
irradiated	NULL
Ad5	NULL
E1A-positive	NULL
tumor	NULL
cells	NULL
to	NULL
induce	NULL
a	NULL
significant	NULL
number	NULL
of	NULL
Ad5	NULL
E1A-specific	NULL
CTLs	NULL
.	NULL

Two	NULL
weeks	NULL
after	NULL
the	NULL
last	NULL
cellular	NULL
immunization	NULL
,	NULL
mice	NULL
were	NULL
injected	NULL
s.c.	NULL
with	NULL
AdS	NULL
EIA	NULL
peptide	NULL
in	NULL
IFA	NULL
.	NULL

At	NULL
defined	NULL
times	NULL
after	NULL
peptide	NULL
injection	NULL
,	NULL
splenocytes	NULL
were	NULL
isolated	NULL
and	NULL
the	NULL
number	NULL
of	NULL
Ad5	NULL
E1A-specific	NULL
CTLs	NULL
was	NULL
determined	NULL
by	NULL
AdS	NULL
E1A-H2-D	NULL
``	NULL
tetramer	NULL
analysis	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
before	NULL
peptide	NULL
injection	NULL
(	NULL
0	NULL
h	NULL
after	NULL
peptide	NULL
injection	NULL
)	NULL
,	NULL
a	NULL
significant	NULL
Ad5	NULL
E1	NULL
A-specific	NULL
CTL	NULL
response	NULL
was	NULL
present	NULL
:	NULL
1.58	NULL
%	NULL
of	NULL
the	NULL
CD8	NULL
*	NULL
splenocytes	NULL
was	NULL
Ad5	NULL
EIA	NULL
specific	NULL
.	NULL

Within	NULL
24	NULL
h	NULL
after	NULL
Ad5	NULL
ElA	NULL
peptide	NULL
injection	NULL
,	NULL
the	NULL
number	NULL
of	NULL
Ad5	NULL
E1	NULL
A-specific	NULL
CTLs	NULL
gradually	NULL
reduced	NULL
to	NULL
levels	NULL
detected	NULL
in	NULL
a	NULL
naive	NULL
mouse	NULL
and	NULL
remained	NULL
unchanged	NULL
up	NULL
to	NULL
2	NULL
wk	NULL
after	NULL
peptide	NULL
injection	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
injection	NULL
results	NULL
in	NULL
physical	NULL
deletion	NULL
of	NULL
Ad5	NULL
E1A-specific	NULL
CTLs	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
observed	NULL
physical	NULL
deletion	NULL
is	NULL
very	NULL
rapid	NULL
,	NULL
as	NULL
is	NULL
the	NULL
appearance	NULL
of	NULL
the	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
in	NULL
the	NULL
spleen	NULL
.	NULL

The	NULL
rapid	NULL
increase	NULL
of	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
concentration	NULL
within	NULL
the	NULL
first	NULL
10	NULL
h	NULL
of	NULL
peptide	NULL
injection	NULL
results	NULL
in	NULL
deletion	NULL
of	NULL
Ad5	NULL
E1A-specific	NULL
CTLs	NULL
in	NULL
that	NULL
same	NULL
time	NULL
period	NULL
.	NULL

Discussion	NULL
Ag	NULL
localization	NULL
,	NULL
dose	NULL
,	NULL
and	NULL
persistence	NULL
determine	NULL
whether	NULL
an	NULL
Ag	NULL
will	NULL
immunize	NULL
or	NULL
tolerize	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Local	NULL
administration	NULL
of	NULL
CTL	NULL
peptides	NULL
in	NULL
adjuvant	NULL
can	NULL
result	NULL
in	NULL
an	NULL
optimal	NULL
induction	NULL
of	NULL
a	NULL
specific	NULL
CTL	NULL
response	NULL
.	NULL

Other	NULL
routes	NULL
of	NULL
delivery	NULL
(	NULL
i.v	NULL
.	NULL

and	NULL
i.p	NULL
.	NULL
)	NULL

that	NULL
result	NULL
in	NULL
a	NULL
rapid	NULL
,	NULL
systemic	NULL
distribution	NULL
and	NULL
high	NULL
Ag	NULL
concentrations	NULL
induce	NULL
CTL	NULL
tolerance	NULL
in	NULL
animals	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
route	NULL
of	NULL
delivery	NULL
does	NULL
not	NULL
always	NULL
predict	NULL
the	NULL
outcome	NULL
of	NULL
peptide-based	NULL
vaccination	NULL
,	NULL
because	NULL
s.c.	NULL
peptide-based	NULL
vaccination	NULL
in	NULL
IFA	NULL
can	NULL
also	NULL
lead	NULL
to	NULL
tolerization	NULL
of	NULL
peptide-specific	NULL
CTLs	NULL
(	NULL
4-6	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
have	NULL
compared	NULL
the	NULL
pharmacokinetics	NULL
of	NULL
a	NULL
T	NULL
cell-tolerizing	NULL
and	NULL
a	NULL
T	NULL
cell-activating	NULL
peptide	NULL
with	NULL
the	NULL
kinetics	NULL
of	NULL
CTL	NULL
induction	NULL
in	NULL
vivo	NULL
.	NULL

The	NULL
results	NULL
provide	NULL
strong	NULL
evidence	NULL
for	NULL
the	NULL
hypothesis	NULL
that	NULL
T	NULL
cell	NULL
activation	NULL
or	NULL
tolerization	NULL
is	NULL
determined	NULL
by	NULL
Ag	NULL
concentration	NULL
over	NULL
time	NULL
and	NULL
Ag	NULL
persistence	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
adjuvants	NULL
to	NULL
prevent	NULL
tolerance	NULL
is	NULL
believed	NULL
to	NULL
reflect	NULL
a	NULL
slow	NULL
Ag	NULL
release	NULL
from	NULL
the	NULL
adjuvant	NULL
that	NULL
results	NULL
in	NULL
an	NULL
extended	NULL
stable	NULL
and	NULL
low	NULL
level	NULL
of	NULL
Ag	NULL
presentation	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
adjuvants	NULL
provide	NULL
an	NULL
Ag	NULL
depot	NULL
,	NULL
allowing	NULL
professional	NULL
APCs	NULL
to	NULL
enter	NULL
the	NULL
vaccine	NULL
site	NULL
and	NULL
collect	NULL
the	NULL
peptide	NULL
.	NULL

These	NULL
Ag-loaded	NULL
APCs	NULL
then	NULL
migrate	NULL
to	NULL
the	NULL
lymph	NULL
nodes	NULL
and	NULL
initiate	NULL
T	NULL
cell	NULL
activation	NULL
(	NULL
22	NULL
)	NULL
.	NULL

This	NULL
study	NULL
presents	NULL
evidence	NULL
that	NULL
the	NULL
activating	NULL
HPV16	NULL
E7	NULL
peptide	NULL
persists	NULL
in	NULL
all	NULL
organs	NULL
longer	NULL
than	NULL
the	NULL
tolerizing	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
as	NULL
a	NULL
result	NULL
of	NULL
a	NULL
slow	NULL
release	NULL
of	NULL
the	NULL
HPV16	NULL
E7	NULL
peptide	NULL
from	NULL
the	NULL
vaccine	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

As	NULL
a	NULL
consequence	NULL
of	NULL
the	NULL
rapid	NULL
diffusion	NULL
of	NULL
the	NULL
Ad5	NULL
E1	NULL
A	NULL
peptide	NULL
from	NULL
the	NULL
vaccine	NULL
site	NULL
,	NULL
the	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
concentration	NULL
reaches	NULL
its	NULL
maximum	NULL
concentration	NULL
in	NULL
a	NULL
relatively	NULL
short	NULL
time	NULL
in	NULL
all	NULL
organs	NULL
,	NULL
A	NULL
150	NULL
100	NULL
CPM	NULL
50	NULL
o	NULL
Th	NULL
0	NULL
5	NULL
10	NULL
15	NULL
]	NULL
20	NULL
25	NULL
30	NULL
35	NULL
Fraction	NULL
CPM	NULL
10	NULL
15	NULL
20	NULL
|25	NULL
30	NULL
35	NULL
Fraction	NULL
FIGURE	NULL
5	NULL
.	NULL

Intact	NULL
Ad5	NULL
ElA	NULL
and	NULL
HPV16	NULL
E7	NULL
peptides	NULL
can	NULL
be	NULL
detected	NULL
24	NULL
h	NULL
after	NULL
injection	NULL
.	NULL

HPLC	NULL
analysis	NULL
of	NULL
homogenates	NULL
obtained	NULL
from	NULL
mice	NULL
injected	NULL
with	NULL
the	NULL
AdS	NULL
E1A	NULL
peptide	NULL
(	NULL
4	NULL
)	NULL
or	NULL
HPV16	NULL
E7	NULL
peptide	NULL
(	NULL
B	NULL
)	NULL
.	NULL

The	NULL
symbols	NULL
represent	NULL
the	NULL
following	NULL
organs	NULL
:	NULL
O	NULL
,	NULL
heart	NULL
;	NULL
[	NULL
_	NULL
]	NULL
,	NULL
lungs	NULL
;	NULL
©	NULL
,	NULL
kidneys	NULL
;	NULL
%	NULL
,	NULL
liver	NULL
;	NULL
F	NULL
,	NULL
intestines	NULL
;	NULL
and	NULL
A	NULL
,	NULL
brain	NULL
.	NULL

The	NULL
arrow	NULL
indicates	NULL
the	NULL
fraction	NULL
in	NULL
which	NULL
the	NULL
purified	NULL
synthetic	NULL
tritiated	NULL
peptide	NULL
eluted	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
7156	NULL
IN	NULL
VIVO	NULL
KINETICS	NULL
OF	NULL
A	NULL
TOLERIZING	NULL
AND	NULL
AN	NULL
ACTIVATING	NULL
PEPTIDE	NULL
A	NULL
C	NULL
2°	NULL
``	NULL
~	NULL
era	NULL
l	NULL
@	NULL
2°	NULL
~	NULL
Era	NULL
%	NULL
__|	NULL
E7	NULL
|	NULL
3	NULL
220	NULL
.	NULL

»	NULL
E7	NULL
‘	NULL
é	NULL
200	NULL
J	NULL
R	NULL
x	NULL
be	NULL
140	NULL
}	NULL
z	NULL
100	NULL
[	NULL
&	NULL
eol	NULL
.	NULL

I	NULL
1	NULL
FIGURE	NULL
6	NULL
.	NULL

Kinetics	NULL
of	NULL
HPV16	NULL
EZ-specific	NULL
CTL	NULL
in-	NULL
_-	NULL
Z	NULL
I	NULL
o	NULL
|g	NULL
1	NULL
a	NULL
6	NULL
I	NULL
zl	NULL
]	NULL
i	NULL
o	NULL
.	NULL

§	NULL
Llc	NULL
.	NULL

,	NULL
a.	NULL
i	NULL
g	NULL
-a-duction	NULL
correlates	NULL
with	NULL
HPV16	NULL
E7	NULL
peptide	NULL
kinetics	NULL
.	NULL

2	NULL
9	NULL
1*	NULL
*O*	NULL
2C	NULL
g	NULL
20	NULL
!	NULL

TO	NULL
Tot	NULL
of	NULL
t	NULL
T	NULL
*	NULL
C57BL/6	NULL
mice	NULL
were	NULL
injected	NULL
with	NULL
HPV16	NULL
E7	NULL
peptide	NULL
,	NULL
o	NULL
1	NULL
o	NULL
e	NULL
and	NULL
spleens	NULL
were	NULL
isolated	NULL
at	NULL
designated	NULL
times	NULL
after	NULL
pep-	NULL
190	NULL
9	NULL
4	NULL
4	NULL
g	NULL
2a	NULL
48	NULL
72	NULL
120	NULL
i168	NULL
ase	NULL
100	NULL
G	NULL
1	NULL
a	NULL
B	NULL
2a	NULL
as	NULL
72	NULL
120	NULL
ios	NULL
aso	NULL
tide	NULL
injection	NULL
.	NULL

HPV16	NULL
E7-	NULL
and	NULL
AdS	NULL
E1A-specific	NULL
Time	NULL
(	NULL
h	NULL
)	NULL
Time	NULL
(	NULL
h	NULL
)	NULL
splenocytes	NULL
were	NULL
used	NULL
in	NULL
an	NULL
ELISPOT	NULL
assay	NULL
measuring	NULL
IFN-y	NULL
release	NULL
(	NULL
A	NULL
and	NULL
C	NULL
,	NULL
respectively	NULL
)	NULL
and	NULL
for	NULL
HPV16	NULL
E7-H2-D	NULL
``	NULL
or	NULL
Ad5	NULL
E1A-H2-D	NULL
``	NULL
tetramer	NULL
staining	NULL
(	NULL
B	NULL
and	NULL
B	NULL
D	NULL
D	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

Splenocytes	NULL
isolated	NULL
from	NULL
mice	NULL
immu-	NULL
nized	NULL
with	NULL
irradiated	NULL
HPV16	NULL
E7	NULL
or	NULL
AdS	NULL
E1A-positive	NULL
1.20	NULL
1.50	NULL
tumor	NULL
cells	NULL
were	NULL
used	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
for	NULL
tetramer	NULL
£	NULL
111152	NULL
)	NULL
I	NULL
122	NULL
I	NULL
Es	NULL
staining	NULL
.	NULL

4.0.40	NULL
m	NULL
0.50	NULL
A	NULL
+	NULL
&	NULL
0.30	NULL
&	NULL
0.40	NULL
5	NULL
2	NULL
0.30	NULL
2	NULL
0.20	NULL
6	NULL
3~	NULL
se	NULL
0.20	NULL
0.10	NULL
0.10	NULL
0.00	NULL
0.00	NULL
0	NULL
1	NULL
4	NULL
8	NULL
24	NULL
48	NULL
72120168336pos	NULL
0	NULL
1	NULL
4	NULL
8	NULL
24	NULL
48	NULL
72i2016833gpos	NULL
Time	NULL
(	NULL
h	NULL
)	NULL
Time	NULL
(	NULL
h	NULL
)	NULL
but	NULL
it	NULL
also	NULL
declines	NULL
more	NULL
rapidly	NULL
than	NULL
the	NULL
HPV16	NULL
E7	NULL
peptide	NULL
concentration	NULL
(	NULL
Figs	NULL
.	NULL

3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

The	NULL
peptide	NULL
kinetics	NULL
offers	NULL
an	NULL
explanation	NULL
for	NULL
the	NULL
observation	NULL
that	NULL
mice	NULL
injected	NULL
with	NULL
Ad5	NULL
E1A-specific	NULL
CTLs	NULL
i.v	NULL
.	NULL

and	NULL
the	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
s.c.	NULL
die	NULL
of	NULL
extensive	NULL
lung	NULL
destruction	NULL
within	NULL
16	NULL
h	NULL
after	NULL
injection	NULL
(	NULL
4	NULL
)	NULL
.	NULL

When	NULL
the	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
reaches	NULL
the	NULL
lungs	NULL
within	NULL
16	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
,	NULL
it	NULL
activates	NULL
Ad5	NULL
E1A-specific	NULL
CTLs	NULL
that	NULL
are	NULL
entrapped	NULL
in	NULL
the	NULL
microvascular	NULL
beds	NULL
of	NULL
the	NULL
lungs	NULL
after	NULL
adoptive	NULL
trans-fer	NULL
.	NULL

Peptides	NULL
will	NULL
bind	NULL
to	NULL
the	NULL
MHC	NULL
class	NULL
I	NULL
molecules	NULL
of	NULL
the	NULL
endothelial	NULL
cells	NULL
,	NULL
and	NULL
the	NULL
activated	NULL
CTLs	NULL
will	NULL
cause	NULL
destruction	NULL
of	NULL
the	NULL
endothelial	NULL
cells	NULL
presenting	NULL
the	NULL
peptide	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
mice	NULL
injected	NULL
simultaneously	NULL
with	NULL
HPV16	NULL
E7-specific	NULL
CTLs	NULL
and	NULL
HPV16	NULL
E7	NULL
peptide	NULL
remained	NULL
alive	NULL
,	NULL
because	NULL
the	NULL
HPV16	NULL
E7	NULL
peptide	NULL
slowly	NULL
egresses	NULL
and	NULL
does	NULL
not	NULL
reach	NULL
its	NULL
maximum	NULL
concentration	NULL
until	NULL
160	NULL
h	NULL
after	NULL
injection	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

At	NULL
that	NULL
time	NULL
,	NULL
the	NULL
HPV16	NULL
E7-specific	NULL
CTLs	NULL
will	NULL
have	NULL
migrated	NULL
from	NULL
the	NULL
lungs	NULL
and	NULL
will	NULL
not	NULL
cause	NULL
the	NULL
lung	NULL
destruction	NULL
as	NULL
observed	NULL
in	NULL
the	NULL
Ad5	NULL
E1A	NULL
peptide-injected	NULL
mice	NULL
.	NULL

Interestingly	NULL
,	NULL
we	NULL
observed	NULL
that	NULL
the	NULL
peptides	NULL
detected	NULL
after	NULL
24	NULL
h	NULL
in	NULL
most	NULL
organs	NULL
were	NULL
intact	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
are	NULL
in	NULL
contrast	NULL
to	NULL
a	NULL
report	NULL
that	NULL
studied	NULL
the	NULL
stability	NULL
of	NULL
a	NULL
MART-1	NULL
peptide	NULL
in	NULL
human	NULL
plasma	NULL
in	NULL
vitro	NULL
in	NULL
which	NULL
the	NULL
peptide	NULL
half-life	NULL
was	NULL
calculated	NULL
to	NULL
be	NULL
22	NULL
s	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Our	NULL
data	NULL
indicate	NULL
that	NULL
both	NULL
Ad5	NULL
E1A	NULL
and	NULL
HPV16	NULL
E7	NULL
peptides	NULL
remained	NULL
in	NULL
circulation	NULL
for	NULL
a	NULL
much	NULL
longer	NULL
period	NULL
.	NULL

Peptides	NULL
may	NULL
be	NULL
protected	NULL
from	NULL
degradation	NULL
by	NULL
binding	NULL
to	NULL
MHC	NULL
class	NULL
I	NULL
molecules	NULL
.	NULL

This	NULL
could	NULL
explain	NULL
the	NULL
difference	NULL
between	NULL
these	NULL
two	NULL
studies	NULL
,	NULL
because	NULL
MHC-expressing	NULL
cells	NULL
are	NULL
absent	NULL
in	NULL
plasma	NULL
.	NULL

One	NULL
exception	NULL
to	NULL
this	NULL
generalization	NULL
is	NULL
the	NULL
intestines	NULL
,	NULL
in	NULL
which	NULL
the	NULL
radioactivity	NULL
was	NULL
recovered	NULL
in	NULL
a	NULL
different	NULL
fraction	NULL
from	NULL
the	NULL
intact	NULL
peptide	NULL
after	NULL
HPLC	NULL
analysis	NULL
,	NULL
indicating	NULL
peptide	NULL
degradation	NULL
.	NULL

This	NULL
should	NULL
not	NULL
be	NULL
surprising	NULL
,	NULL
because	NULL
the	NULL
intestines	NULL
contain	NULL
both	NULL
pro-teases	NULL
and	NULL
bacteria	NULL
,	NULL
which	NULL
may	NULL
have	NULL
degraded	NULL
the	NULL
peptides	NULL
.	NULL

The	NULL
mechanism	NULL
by	NULL
which	NULL
the	NULL
peptide-specific	NULL
CTLs	NULL
are	NULL
tolerized	NULL
is	NULL
not	NULL
fully	NULL
understood	NULL
.	NULL

However	NULL
,	NULL
based	NULL
on	NULL
the	NULL
kinetics	NULL
of	NULL
the	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
,	NULL
we	NULL
infer	NULL
that	NULL
tolerance	NULL
is	NULL
likely	NULL
induced	NULL
by	NULL
activation-induced	NULL
cell	NULL
death	NULL
(	NULL
AICD	NULL
)	NULL
.	NULL

AICD	NULL
occurs	NULL
as	NULL
the	NULL
consequence	NULL
of	NULL
repeated	NULL
antigenic	NULL
stimulation	NULL
of	NULL
T	NULL
cells	NULL
and	NULL
is	NULL
mediated	NULL
by	NULL
Fas-Fas	NULL
ligand	NULL
interactions	NULL
in	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
(	NULL
24	NULL
)	NULL
and	NULL
engagement	NULL
of	NULL
TNFRs	NULL
in	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
(	NULL
25	NULL
)	NULL
.	NULL

We	NULL
show	NULL
in	NULL
the	NULL
spleen	NULL
that	NULL
Ad5	NULL
E1A	NULL
peptide-specific	NULL
CTLs	NULL
are	NULL
confronted	NULL
with	NULL
a	NULL
rapid	NULL
influx	NULL
of	NULL
a	NULL
high	NULL
peptide	NULL
concentration	NULL
within	NULL
24	NULL
h	NULL
after	NULL
peptide	NULL
injection	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

The	NULL
analysis	NULL
of	NULL
the	NULL
Ad5	NULL
E1	NULL
A-specific	NULL
CTL	NULL
precursor	NULL
frequency	NULL
obtained	NULL
from	NULL
preimmunized	NULL
mice	NULL
after	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
injection	NULL
demonstrated	NULL
that	NULL
,	NULL
within	NULL
24	NULL
h	NULL
after	NULL
peptide	NULL
injection	NULL
,	NULL
the	NULL
number	NULL
of	NULL
preexisting	NULL
AdS	NULL
E1A-specific	NULL
CTL	NULL
(	NULL
1.6	NULL
%	NULL
of	NULL
the	NULL
CD8	NULL
*	NULL
T	NULL
cell	NULL
population	NULL
)	NULL
was	NULL
significantly	NULL
reduced	NULL
.	NULL

We	NULL
propose	NULL
that	NULL
this	NULL
is	NULL
the	NULL
result	NULL
of	NULL
AICD	NULL
,	NULL
even	NULL
though	NULL
we	NULL
did	NULL
not	NULL
actually	NULL
measure	NULL
apoptosis	NULL
.	NULL

This	NULL
is	NULL
in	NULL
agreement	NULL
with	NULL
a	NULL
study	NULL
showing	NULL
that	NULL
i.p	NULL
.	NULL

injection	NULL
of	NULL
high	NULL
peptide	NULL
doses	NULL
,	NULL
resulting	NULL
in	NULL
systemic	NULL
distribution	NULL
,	NULL
readily	NULL
deleted	NULL
their	NULL
specific	NULL
CTLs	NULL
in	NULL
wild-type	NULL
mice	NULL
.	NULL

However	NULL
,	NULL
in	NULL
TNFR/Fas	NULL
double-knockout	NULL
mice	NULL
,	NULL
i.p	NULL
.	NULL

injection	NULL
of	NULL
peptide	NULL
did	NULL
not	NULL
induce	NULL
AICD	NULL
,	NULL
suggesting	NULL
that	NULL
peptide-induced	NULL
tolerance	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
these	NULL
two	NULL
death	NULL
receptors	NULL
(	NULL
26	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
a	NULL
slow	NULL
buildup	NULL
of	NULL
the	NULL
HPV16	NULL
E7	NULL
peptide	NULL
and	NULL
persistence	NULL
of	NULL
the	NULL
peptide	NULL
in	NULL
lymphoid	NULL
organs	NULL
seems	NULL
optimal	NULL
for	NULL
immunization	NULL
.	NULL

This	NULL
is	NULL
supported	NULL
by	NULL
our	NULL
finding	NULL
that	NULL
the	NULL
increased	NULL
HPV16	NULL
E7	NULL
peptide	NULL
concentration	NULL
is	NULL
closely	NULL
followed	NULL
by	NULL
an	NULL
increase	NULL
in	NULL
HPV16	NULL
E7	NULL
CTLs	NULL
(	NULL
Fig	NULL
.	NULL

%	NULL
of	NULL
CDB+E1A*	NULL
e	NULL
s-	NULL
os	NULL
p	NULL
§	NULL
3	NULL
S8	NULL
S	NULL
3	NULL
0	NULL
1	NULL
4	NULL
8	NULL
24	NULL
48	NULL
72120168	NULL
336neg	NULL
Time	NULL
(	NULL
h	NULL
)	NULL
FIGURE	NULL
7	NULL
.	NULL

Ad5	NULL
E1A-specific	NULL
CTLs	NULL
are	NULL
readily	NULL
deleted	NULL
after	NULL
Ad5	NULL
ELA	NULL
peptide	NULL
injection	NULL
.	NULL

C57BL/6	NULL
mice	NULL
were	NULL
preimmunized	NULL
with	NULL
irradiated	NULL
Ad5	NULL
E1A-positive	NULL
tumor	NULL
cells	NULL
followed	NULL
by	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
injection	NULL
2	NULL
wk	NULL
later	NULL
.	NULL

At	NULL
different	NULL
times	NULL
after	NULL
peptide	NULL
injection	NULL
,	NULL
spleens	NULL
were	NULL
isolated	NULL
and	NULL
the	NULL
number	NULL
of	NULL
AdS	NULL
E1A-specific	NULL
CTLs	NULL
quantified	NULL
by	NULL
AdS	NULL
tetramer	NULL
staining	NULL
.	NULL

Splenocytes	NULL
isolated	NULL
from	NULL
naive	NULL
mice	NULL
were	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
6	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

Another	NULL
possible	NULL
explanation	NULL
for	NULL
the	NULL
reduction	NULL
of	NULL
AdS	NULL
E1A-specific	NULL
CTLs	NULL
could	NULL
be	NULL
retrafficking	NULL
of	NULL
these	NULL
CTLs	NULL
.	NULL

However	NULL
,	NULL
because	NULL
the	NULL
AdS	NULL
E1A	NULL
peptide	NULL
spreads	NULL
to	NULL
all	NULL
organs	NULL
with	NULL
similar	NULL
kinetics	NULL
,	NULL
this	NULL
seems	NULL
less	NULL
likely	NULL
.	NULL

It	NULL
remains	NULL
to	NULL
be	NULL
answered	NULL
why	NULL
the	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
displays	NULL
such	NULL
different	NULL
kinetics	NULL
compared	NULL
with	NULL
the	NULL
HPV16	NULL
E7	NULL
peptide	NULL
.	NULL

Differences	NULL
in	NULL
kinetics	NULL
may	NULL
be	NULL
the	NULL
consequence	NULL
of	NULL
a	NULL
combination	NULL
of	NULL
intrinsic	NULL
peptide	NULL
characteristics	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
hydrophobicity	NULL
,	NULL
charge	NULL
,	NULL
structure	NULL
,	NULL
and	NULL
MHC	NULL
class	NULL
I	NULL
binding	NULL
affinities	NULL
of	NULL
the	NULL
peptide	NULL
.	NULL

Comparison	NULL
of	NULL
these	NULL
two	NULL
peptide	NULL
sequences	NULL
revealed	NULL
that	NULL
the	NULL
AdS	NULL
E1A	NULL
peptide	NULL
is	NULL
more	NULL
hydrophilic	NULL
than	NULL
the	NULL
HPV16	NULL
E7	NULL
peptide	NULL
.	NULL

However	NULL
,	NULL
tolerance	NULL
could	NULL
not	NULL
be	NULL
prevented	NULL
by	NULL
using	NULL
an	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
that	NULL
was	NULL
engineered	NULL
to	NULL
increase	NULL
hydrophobicity	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
AdS	NULL
E1A	NULL
peptide	NULL
is	NULL
negatively	NULL
charged	NULL
as	NULL
compared	NULL
with	NULL
a	NULL
positively	NULL
charged	NULL
HPV16	NULL
E7	NULL
.	NULL

Other	NULL
structural	NULL
features	NULL
,	NULL
such	NULL
as	NULL
the	NULL
presence	NULL
of	NULL
aromatic	NULL
amino	NULL
acids	NULL
in	NULL
HPV16	NULL
E7	NULL
and	NULL
not	NULL
in	NULL
Ad5	NULL
E1A	NULL
,	NULL
may	NULL
contribute	NULL
to	NULL
their	NULL
functional	NULL
differences	NULL
.	NULL

Another	NULL
important	NULL
difference	NULL
is	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
Ad5	NULL
E1A	NULL
peptide	NULL
has	NULL
a	NULL
100-fold	NULL
higher	NULL
binding	NULL
affinity	NULL
for	NULL
the	NULL
H2-D	NULL
``	NULL
°	NULL
molecule	NULL
than	NULL
for	NULL
the	NULL
HPV16	NULL
E7	NULL
peptide	NULL
(	NULL
28	NULL
)	NULL
.	NULL

However	NULL
,	NULL
this	NULL
feature	NULL
by	NULL
itself	NULL
does	NULL
not	NULL
explain	NULL
the	NULL
functional	NULL
difference	NULL
between	NULL
the	NULL
two	NULL
peptides	NULL
,	NULL
because	NULL
MHC-peptide	NULL
binding	NULL
analysis	NULL
of	NULL
a	NULL
number	NULL
of	NULL
T	NULL
cell-tolerizing	NULL
and	NULL
-activating	NULL
peptides	NULL
showed	NULL
that	NULL
tolerizing	NULL
peptides	NULL
do	NULL
not	NULL
have	NULL
a	NULL
consistently	NULL
higher	NULL
binding	NULL
affinity	NULL
than	NULL
activating	NULL
peptides	NULL
(	NULL
29	NULL
)	NULL
.	NULL

The	NULL
pharmacokinetic	NULL
properties	NULL
of	NULL
other	NULL
T	NULL
cell-tolerizing	NULL
and	NULL
-activating	NULL
peptides	NULL
should	NULL
be	NULL
analyzed	NULL
to	NULL
determine	NULL
whether	NULL
differences	NULL
in	NULL
pharmacokinetics	NULL
could	NULL
indeed	NULL
predict	NULL
the	NULL
tolerizing	NULL
or	NULL
activating	NULL
property	NULL
of	NULL
peptides	NULL
in	NULL
general	NULL
.	NULL

Ultimately	NULL
,	NULL
prediction	NULL
of	NULL
the	NULL
effects	NULL
that	NULL
peptides	NULL
may	NULL
have	NULL
on	NULL
the	NULL
immune	NULL
system	NULL
using	NULL
pharmacokinetic	NULL
profiles	NULL
may	NULL
increase	NULL
the	NULL
safety	NULL
and	NULL
efficacy	NULL
of	NULL
peptide-based	NULL
vaccinations	NULL
in	NULL
humans	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
the	NULL
tetramer	NULL
core	NULL
facility	NULL
at	NULL
National	NULL
Institute	NULL
of	NULL
Allergy	NULL
and	NULL
Infectious	NULL
Diseases	NULL
for	NULL
providing	NULL
the	NULL
tetramers	NULL
used	NULL
in	NULL
this	NULL
study	NULL
.	NULL

We	NULL
thank	NULL
Dr.	NULL
Thomas	NULL
Ellis	NULL
for	NULL
critically	NULL
reading	NULL
the	NULL
manuscript	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Kast	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
L.	NULL
Roux	NULL
,	NULL
J.	NULL
Curren	NULL
,	NULL
H.	NULL
J.	NULL
Blom	NULL
,	NULL
A.	NULL
C.	NULL
Voordouw	NULL
,	NULL
R.	NULL
H.	NULL
Meloen	NULL
,	NULL
D.	NULL
Kolakofsky	NULL
,	NULL
and	NULL
C.	NULL
J.	NULL
Melief	NULL
.	NULL

1991	NULL
.	NULL

Protection	NULL
against	NULL
lethal	NULL
Sendai	NULL
virus	NULL
infection	NULL
by	NULL
in	NULL
vivo	NULL
priming	NULL
of	NULL
virus-specific	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
with	NULL
a	NULL
free	NULL
synthetic	NULL
peptide	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:2283	NULL
.	NULL

2	NULL
.	NULL

Schulz	NULL
,	NULL
M.	NULL
,	NULL
R.	NULL
M.	NULL
Zinkernagel	NULL
,	NULL
and	NULL
H.	NULL
Hengartner	NULL
.	NULL

1991	NULL
.	NULL

Peptide-induced	NULL
antiviral	NULL
protection	NULL
by	NULL
cytotoxic	NULL
T	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:991	NULL
.	NULL

3	NULL
.	NULL

Feltkamp	NULL
,	NULL
M.	NULL
C.	NULL
W.	NULL
,	NULL
H.	NULL
L.	NULL
Smits	NULL
,	NULL
M.	NULL
P.	NULL
M.	NULL
Vietboom	NULL
,	NULL
R.	NULL
P.	NULL
Minnaar	NULL
,	NULL
B.	NULL
M.	NULL
de	NULL
Jongh	NULL
,	NULL
J.	NULL
W.	NULL
Drijfhout	NULL
,	NULL
J.	NULL
ter	NULL
Schegget	NULL
,	NULL
C.	NULL
J.	NULL
M.	NULL
Melief	NULL
,	NULL
and	NULL
W.	NULL
M.	NULL
Kast	NULL
.	NULL

1993	NULL
.	NULL

Vaccination	NULL
with	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
epitope-containing	NULL
peptide	NULL
protects	NULL
against	NULL
a	NULL
tumor	NULL
induced	NULL
by	NULL
human	NULL
papillomavirus	NULL
type	NULL
16-transformed	NULL
cells	NULL
.	NULL

Kur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

23:2242	NULL
.	NULL

4	NULL
.	NULL

Toes	NULL
,	NULL
R.	NULL
E.	NULL
M.	NULL
,	NULL
R.	NULL
Offringa	NULL
,	NULL
R.	NULL
J.	NULL
J.	NULL
Blom	NULL
,	NULL
C.	NULL
J.	NULL
M.	NULL
Melief	NULL
,	NULL
and	NULL
W.	NULL
M.	NULL
Kast	NULL
.	NULL

1996	NULL
.	NULL

Peptide	NULL
vaccination	NULL
can	NULL
lead	NULL
to	NULL
enhanced	NULL
tumor	NULL
growth	NULL
through	NULL
specific	NULL
T-cell	NULL
tolerance	NULL
induction	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93:7855	NULL
.	NULL

5	NULL
.	NULL

Toes	NULL
,	NULL
R.	NULL
E.	NULL
M.	NULL
,	NULL
R.	NULL
J.	NULL
J.	NULL
Blom	NULL
,	NULL
R.	NULL
Offringa	NULL
,	NULL
W.	NULL
M.	NULL
Kast	NULL
,	NULL
and	NULL
C.	NULL
J.	NULL
M.	NULL
Melief	NULL
.	NULL

1996	NULL
.	NULL

Enhanced	NULL
tumor	NULL
outgrowth	NULL
after	NULL
peptide	NULL
vaccination	NULL
:	NULL
functional	NULL
deletion	NULL
of	NULL
tu-mor-specific	NULL
CTL	NULL
induced	NULL
by	NULL
peptide	NULL
vaccination	NULL
can	NULL
lead	NULL
to	NULL
the	NULL
inability	NULL
to	NULL
reject	NULL
tumors	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

156:3911	NULL
.	NULL

6	NULL
.	NULL

Nicland	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
D.	NULL
M.	NULL
Da	NULL
Silva	NULL
,	NULL
M.	NULL
P.	NULL
Velders	NULL
,	NULL
K.	NULL
E.	NULL
de	NULL
Visser	NULL
,	NULL
J.	NULL
T.	NULL
Schiller	NULL
,	NULL
M.	NULL
Muller	NULL
,	NULL
and	NULL
W.	NULL
M.	NULL
Kast	NULL
.	NULL

1999	NULL
.	NULL

Chimeric	NULL
papillomavirus	NULL
virus-like	NULL
particles	NULL
induce	NULL
a	NULL
murine	NULL
self-antigen-specific	NULL
protective	NULL
and	NULL
therapeutic	NULL
antitumor	NULL
immune	NULL
response	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
.	NULL

Biochem	NULL
.	NULL

73:145	NULL
.	NULL

7	NULL
.	NULL

Wang	NULL
,	NULL
F.	NULL
,	NULL
E.	NULL
Bade	NULL
,	NULL
C.	NULL
Kuniyoshi	NULL
,	NULL
L.	NULL
Spears	NULL
,	NULL
G.	NULL
Jeffrey	NULL
,	NULL
V.	NULL
Marty	NULL
,	NULL
S.	NULL
Groshen	NULL
,	NULL
and	NULL
J.	NULL
Weber	NULL
.	NULL

1999	NULL
.	NULL

Phase	NULL
I	NULL
trial	NULL
of	NULL
a	NULL
MART-1	NULL
peptide	NULL
vaccine	NULL
with	NULL
incomplete	NULL
Freund	NULL
's	NULL
adjuvant	NULL
for	NULL
resected	NULL
high-risk	NULL
melanoma	NULL
.	NULL

Clin	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

5:2756	NULL
.	NULL

8	NULL
.	NULL

Muderspach	NULL
,	NULL
L.	NULL
,	NULL
S.	NULL
Wilczyneki	NULL
,	NULL
L.	NULL
Roman	NULL
,	NULL
L.	NULL
Bade	NULL
,	NULL
J.	NULL
Felix	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

Small	NULL
,	NULL
W.	NULL
M.	NULL
Kast	NULL
,	NULL
G.	NULL
Fascia	NULL
,	NULL
V.	NULL
Marty	NULL
,	NULL
and	NULL
J.	NULL
Weber	NULL
.	NULL

2000	NULL
.	NULL

A	NULL
phase	NULL
I	NULL
trial	NULL
of	NULL
a	NULL
human	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

7157	NULL
papillomavirus	NULL
(	NULL
HPV	NULL
)	NULL
peptide	NULL
vaccine	NULL
for	NULL
women	NULL
with	NULL
high-grade	NULL
cervical	NULL
and	NULL
vul-var	NULL
intracpithelial	NULL
neoplasia	NULL
who	NULL
are	NULL
HPV	NULL
16	NULL
positive	NULL
.	NULL

Clin	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

6:3406.	NULL
.	NULL

Valmori	NULL
,	NULL
D.	NULL
,	NULL
V.	NULL
Dutoit	NULL
,	NULL
V.	NULL
Rubio-Godoy	NULL
,	NULL
C.	NULL
Chambaz	NULL
,	NULL
D.	NULL
Lienard	NULL
,	NULL
P.	NULL
Guillaume	NULL
,	NULL
P.	NULL
Romero	NULL
,	NULL
J.	NULL
C.	NULL
Cerottini	NULL
,	NULL
and	NULL
D.	NULL
Rimoldi	NULL
.	NULL

2001	NULL
.	NULL

Frequent	NULL
cytolytic	NULL
T-cell	NULL
responses	NULL
to	NULL
peptide	NULL
MAGE-A10	NULL
;	NULL
5	NULL
,	NULL
;	NULL
4	NULL
,	NULL
in	NULL
melanoma	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

61:509	NULL
.	NULL

Lee	NULL
,	NULL
K.	NULL
H.	NULL
,	NULL
E.	NULL
Wang	NULL
,	NULL
M.	NULL
B.	NULL
Nielsen	NULL
,	NULL
J.	NULL
Wunderlich	NULL
,	NULL
S.	NULL
Migueles	NULL
,	NULL
M.	NULL
Connors	NULL
,	NULL
S.	NULL
M.	NULL
Steinberg	NULL
,	NULL
S.	NULL
A.	NULL
Rosenberg	NULL
,	NULL
and	NULL
F.	NULL
M.	NULL
Marincola	NULL
.	NULL

1999	NULL
.	NULL

Increased	NULL
vaccine-specific	NULL
T	NULL
cell	NULL
frequency	NULL
after	NULL
peptide-based	NULL
vaccination	NULL
correlates	NULL
with	NULL
increased	NULL
susceptibility	NULL
to	NULL
in	NULL
vitro	NULL
stimulation	NULL
but	NULL
does	NULL
not	NULL
lead	NULL
to	NULL
tumor	NULL
regression	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

163:6292	NULL
.	NULL

Marchand	NULL
,	NULL
M.	NULL
,	NULL
N.	NULL
Van	NULL
Baren	NULL
,	NULL
P.	NULL
Weynants	NULL
,	NULL
V.	NULL
Brichard	NULL
,	NULL
B.	NULL
Dreno	NULL
,	NULL
M.	NULL
H.	NULL
Tessier	NULL
,	NULL
E.	NULL
Rankin	NULL
,	NULL
G.	NULL
Parmiani	NULL
,	NULL
F.	NULL
Arienti	NULL
,	NULL
Y.	NULL
Humblet	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1999	NULL
.	NULL

Tumor	NULL
regressions	NULL
observed	NULL
in	NULL
patients	NULL
with	NULL
metastatic	NULL
melanoma	NULL
treated	NULL
with	NULL
an	NULL
antigenic	NULL
peptide	NULL
encoded	NULL
by	NULL
gene	NULL
MAGE-3	NULL
and	NULL
presented	NULL
by	NULL
HLA-A1	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
80:219	NULL
.	NULL

Gjertsen	NULL
,	NULL
M.	NULL
K.	NULL
,	NULL
A.	NULL
Bakka	NULL
,	NULL
J.	NULL
Breivik	NULL
,	NULL
I.	NULL
Sacterdal	NULL
,	NULL
B.	NULL
G.	NULL
Solheim	NULL
,	NULL
O.	NULL
Soreide	NULL
,	NULL
E.	NULL
Thorsby	NULL
,	NULL
and	NULL
G.	NULL
Gaudernack	NULL
.	NULL

1995	NULL
.	NULL

Vaccination	NULL
with	NULL
mutant	NULL
ras	NULL
peptides	NULL
and	NULL
induction	NULL
of	NULL
T-cell	NULL
responsiveness	NULL
in	NULL
pancreatic	NULL
carcinoma	NULL
patients	NULL
carrying	NULL
the	NULL
corresponding	NULL
RAS	NULL
mutation	NULL
.	NULL

Lancet	NULL
346:1399	NULL
,	NULL
Kast	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
ed	NULL
.	NULL

2000	NULL
.	NULL

Peptide-Based	NULL
Cancer	NULL
Vaccines	NULL
.	NULL

Eurekab.com	NULL
,	NULL
Austin	NULL
.	NULL

Marchand	NULL
,	NULL
M.	NULL
,	NULL
P.	NULL
Weynants	NULL
,	NULL
E.	NULL
Rankin	NULL
,	NULL
F.	NULL
Arienti	NULL
,	NULL
F.	NULL
Belli	NULL
,	NULL
G.	NULL
Parmiani	NULL
,	NULL
N.	NULL
Cascinelli	NULL
,	NULL
A.	NULL
Bourlond	NULL
,	NULL
R.	NULL
Vanwijck	NULL
,	NULL
Y.	NULL
Humblet	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
.	NULL

Tumor	NULL
regression	NULL
responses	NULL
in	NULL
melanoma	NULL
patients	NULL
treated	NULL
with	NULL
a	NULL
peptide	NULL
encoded	NULL
by	NULL
gene	NULL
MAGE-3	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
63:883	NULL
.	NULL

Khieif	NULL
,	NULL
S.	NULL
N.	NULL
,	NULL
S.	NULL
I.	NULL
Abrams	NULL
,	NULL
J.	NULL
M.	NULL
Hamilton	NULL
,	NULL
E.	NULL
Bergmann-Leitner	NULL
,	NULL
A.	NULL
Chen	NULL
,	NULL
A.	NULL
Bastian	NULL
,	NULL
S.	NULL
Bernstein	NULL
,	NULL
Y.	NULL
Chung	NULL
,	NULL
C.	NULL
J.	NULL
Allegra	NULL
,	NULL
and	NULL
J.	NULL
Schlom	NULL
.	NULL

1999	NULL
.	NULL

A	NULL
phase	NULL
I	NULL
vaccine	NULL
trial	NULL
with	NULL
peptides	NULL
reflecting	NULL
ras	NULL
oncogene	NULL
mutations	NULL
of	NULL
solid	NULL
tumors	NULL
.	NULL

J.	NULL
Immunother	NULL
.	NULL

22:155	NULL
.	NULL

Kast	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
R.	NULL
Offringa	NULL
,	NULL
P.	NULL
J.	NULL
Peters	NULL
,	NULL
A.	NULL
C.	NULL
Voordouw	NULL
,	NULL
R.	NULL
H.	NULL
Meloen	NULL
,	NULL
A.	NULL
J.	NULL
van	NULL
der	NULL
Bb	NULL
,	NULL
and	NULL
C.	NULL
J.	NULL
M.	NULL
Melief	NULL
.	NULL

1989	NULL
.	NULL

Eradication	NULL
of	NULL
adenovirus	NULL
El-induced	NULL
tumors	NULL
by	NULL
E1A-specific	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

Cell	NULL
59:603	NULL
.	NULL

Benzinger	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
D.	NULL
M.	NULL
Gregory	NULL
,	NULL
T.	NULL
S.	NULL
Burkoth	NULL
,	NULL
H.	NULL
Miller-Auer	NULL
,	NULL
D.	NULL
G.	NULL
Lynn	NULL
,	NULL
R.	NULL
E.	NULL
Botto	NULL
,	NULL
and	NULL
S.	NULL
C.	NULL
Meredith	NULL
.	NULL

1998	NULL
.	NULL

Propagating	NULL
structure	NULL
of	NULL
Alzheimer	NULL
's	NULL
35	NULL
is	NULL
parallel	NULL
B-sheet	NULL
with	NULL
residues	NULL
in	NULL
exact	NULL
register	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
95:13407	NULL
.	NULL

Braddock	NULL
,	NULL
D.	NULL
T.	NULL
,	NULL
K.	NULL
O.	NULL
Mercurius	NULL
,	NULL
R.	NULL
M.	NULL
Subramanian	NULL
,	NULL
S.	NULL
R.	NULL
Dominguez	NULL
,	NULL
P.	NULL
F.	NULL
Davies	NULL
,	NULL
and	NULL
S.	NULL
C.	NULL
Meredith	NULL
.	NULL

1996	NULL
.	NULL

Conformationally	NULL
specific	NULL
enhancement	NULL
of	NULL
receptor-mediated	NULL
LDL	NULL
binding	NULL
and	NULL
internalization	NULL
by	NULL
peptide	NULL
models	NULL
of	NULL
a	NULL
conserved	NULL
anionic	NULL
N-terminal	NULL
domain	NULL
of	NULL
human	NULL
apolipoprotein	NULL
E.	NULL
Biochemistry	NULL
35:13975	NULL
.	NULL

Zinkernagel	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
S.	NULL
Ehl	NULL
,	NULL
P.	NULL
Aichele	NULL
,	NULL
S.	NULL
Ochen	NULL
,	NULL
T.	NULL
Kundig	NULL
,	NULL
and	NULL
H.	NULL
Hengartner	NULL
.	NULL

1997	NULL
.	NULL

Antigen	NULL
localisation	NULL
regulates	NULL
immune	NULL
responses	NULL
in	NULL
a	NULL
dose-	NULL
and	NULL
time-depen-dent	NULL
fashion	NULL
:	NULL
a	NULL
geographical	NULL
view	NULL
of	NULL
immune	NULL
reactivity	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

156:199	NULL
.	NULL

Aichele	NULL
,	NULL
P.	NULL
,	NULL
K.	NULL
Brduscha-Riem	NULL
,	NULL
R.	NULL
M.	NULL
Zinkernagel	NULL
,	NULL
H.	NULL
Hengartner	NULL
,	NULL
and	NULL
H.	NULL
Pircher	NULL
.	NULL

1995	NULL
.	NULL

T	NULL
cell	NULL
priming	NULL
versus	NULL
T	NULL
cell	NULL
tolerance	NULL
induced	NULL
by	NULL
synthetic	NULL
peptides	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

182:261	NULL
.	NULL

Mullbacher	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
R.	NULL
T.	NULL
Hla	NULL
.	NULL

1993	NULL
.	NULL

In	NULL
vivo	NULL
administration	NULL
of	NULL
major	NULL
histocom-patibility	NULL
complex	NULL
class	NULL
-specific	NULL
peptides	NULL
from	NULL
influenza	NULL
virus	NULL
induced	NULL
specific	NULL
cytotoxic	NULL
T	NULL
cell	NULL
hyporesponsiveness	NULL
.	NULL

Kur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

23:2526	NULL
.	NULL

Barratt-Boyes	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
M.	NULL
I.	NULL
Zimmer	NULL
,	NULL
L.	NULL
A.	NULL
Harshyne	NULL
,	NULL
E.	NULL
M.	NULL
Meyer	NULL
,	NULL
S.	NULL
C.	NULL
Watkins	NULL
,	NULL
S.	NULL
Capuano	NULL
,	NULL
3rd	NULL
,	NULL
M.	NULL
Murphey-Corb	NULL
,	NULL
L.	NULL
D.	NULL
Falo	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
A.	NULL
D.	NULL
Donnenberg	NULL
.	NULL

2000	NULL
.	NULL

Maturation	NULL
and	NULL
trafficking	NULL
of	NULL
monocyte-derived	NULL
dendritic	NULL
cells	NULL
in	NULL
monkeys	NULL
:	NULL
implications	NULL
for	NULL
dendritic	NULL
cell-based	NULL
vaccines	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

164:2487	NULL
.	NULL

Brinckerhoff	NULL
,	NULL
L.	NULL
H.	NULL
,	NULL
V.	NULL
V.	NULL
Kalashnikov	NULL
,	NULL
L.	NULL
W.	NULL
Thompson	NULL
,	NULL
G.	NULL
V.	NULL
Yamschikov	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

Pierce	NULL
,	NULL
H.	NULL
S.	NULL
Galavotti	NULL
,	NULL
V.	NULL
H.	NULL
Engelhard	NULL
,	NULL
and	NULL
C.	NULL
L.	NULL
Slingluff	NULL
.	NULL

1999	NULL
.	NULL

Terminal	NULL
modifications	NULL
inhibit	NULL
proteolytic	NULL
degradation	NULL
of	NULL
an	NULL
immunogenic	NULL
Mart-1	NULL
,	NULL
;	NULL
35	NULL
peptide	NULL
:	NULL
implications	NULL
for	NULL
peptide	NULL
vaccines	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
83:326	NULL
.	NULL

Ju	NULL
,	NULL
S.	NULL
T.	NULL
,	NULL
D.	NULL
J.	NULL
Panka	NULL
,	NULL
H.	NULL
Cui	NULL
,	NULL
R.	NULL
Ettinger	NULL
,	NULL
M.	NULL
el-Khatib	NULL
,	NULL
D.	NULL
H.	NULL
Sher	NULL
,	NULL
B	NULL
.	NULL

Z.	NULL
Stanger	NULL
,	NULL
and	NULL
A.	NULL
Marshak-Rothstein	NULL
.	NULL

1995	NULL
.	NULL

Fas	NULL
(	NULL
CD95	NULL
)	NULL
/FasL	NULL
interactions	NULL
required	NULL
for	NULL
programmed	NULL
cell	NULL
death	NULL
after	NULL
T-cell	NULL
activation	NULL
.	NULL

Nature	NULL
373:444	NULL
.	NULL

Speiser	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
E.	NULL
Sebzda	NULL
,	NULL
T.	NULL
Ohteki	NULL
,	NULL
M.	NULL
F.	NULL
Bachmann	NULL
,	NULL
K.	NULL
Pfeffer	NULL
,	NULL
T.	NULL
W.	NULL
Mak	NULL
,	NULL
and	NULL
P.	NULL
S.	NULL
Ohashi	NULL
.	NULL

1996	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
p55	NULL
mediates	NULL
deletion	NULL
of	NULL
peripheral	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
in	NULL
vivo	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

26:3055	NULL
.	NULL

Nguyen	NULL
,	NULL
L.	NULL
T.	NULL
,	NULL
K.	NULL
McKall-Faienza	NULL
,	NULL
A.	NULL
Zakarian	NULL
,	NULL
D.	NULL
E.	NULL
Speiser	NULL
,	NULL
T.	NULL
W.	NULL
Mak	NULL
,	NULL
and	NULL
P.	NULL
S.	NULL
Ohashi	NULL
.	NULL

2000	NULL
.	NULL

TNF	NULL
receptor	NULL
1	NULL
(	NULL
TNFR1	NULL
)	NULL
and	NULL
CD95	NULL
are	NULL
not	NULL
required	NULL
for	NULL
T	NULL
cell	NULL
deletion	NULL
after	NULL
virus	NULL
infection	NULL
but	NULL
contribute	NULL
to	NULL
peptide-induced	NULL
deletion	NULL
under	NULL
limited	NULL
conditions	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

30:683	NULL
.	NULL

Toes	NULL
,	NULL
R.	NULL
E.	NULL
M.	NULL
,	NULL
E.	NULL
I.	NULL
H.	NULL
van	NULL
der	NULL
Voort	NULL
,	NULL
S.	NULL
P.	NULL
Schoenberger	NULL
,	NULL
J.	NULL
W.	NULL
Drijfhout	NULL
,	NULL
L.	NULL
van	NULL
Bloois	NULL
,	NULL
G.	NULL
Storm	NULL
,	NULL
W.	NULL
M.	NULL
Kast	NULL
,	NULL
R.	NULL
Offringa	NULL
,	NULL
and	NULL
C.	NULL
J.	NULL
M.	NULL
Melief	NULL
.	NULL

1998	NULL
.	NULL

Enhancement	NULL
of	NULL
tumor	NULL
outgrowth	NULL
through	NULL
CTL	NULL
tolerization	NULL
after	NULL
peptide	NULL
vaccination	NULL
is	NULL
avoided	NULL
by	NULL
peptide	NULL
presentation	NULL
on	NULL
dendritic	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

160	NULL
;	NULL
4449	NULL
.	NULL

Neisig	NULL
,	NULL
A.	NULL
,	NULL
J.	NULL
Roelse	NULL
,	NULL
A.	NULL
J.	NULL
Sijts	NULL
,	NULL
F.	NULL
Ossendorp	NULL
,	NULL
M.	NULL
C.	NULL
Feltkamp	NULL
,	NULL
W.	NULL
M.	NULL
Kast	NULL
,	NULL
C.	NULL
J.	NULL
M.	NULL
Melief	NULL
,	NULL
and	NULL
J.	NULL
J.	NULL
Neefjes	NULL
.	NULL

1995	NULL
.	NULL

Major	NULL
differences	NULL
in	NULL
transporter	NULL
associated	NULL
with	NULL
antigen	NULL
presentation	NULL
(	NULL
TAP	NULL
)	NULL
-dependent	NULL
translocation	NULL
of	NULL
MHC	NULL
class	NULL
I-presentable	NULL
peptides	NULL
and	NULL
the	NULL
effect	NULL
of	NULL
flanking	NULL
sequences	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:1273	NULL
.	NULL

Feltkamp	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
M.	NULL
P.	NULL
Vierboom	NULL
,	NULL
W.	NULL
M.	NULL
Kast	NULL
,	NULL
and	NULL
C.	NULL
J.	NULL
M.	NULL
Melief	NULL
.	NULL

1994	NULL
.	NULL

Efficient	NULL
MHC	NULL
class	NULL
I-peptide	NULL
binding	NULL
is	NULL
required	NULL
but	NULL
does	NULL
not	NULL
ensure	NULL
MHC	NULL
class	NULL
T-restricted	NULL
immunogenicity	NULL
.	NULL

Mol	NULL
.	NULL

Immunol	NULL
.	NULL

31:1391	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL

